EP2769985B1 - Polypeptides possédant une activité de transporteur d'acide dicarboxylique en C4 et polynucléotides codant pour ces derniers - Google Patents

Polypeptides possédant une activité de transporteur d'acide dicarboxylique en C4 et polynucléotides codant pour ces derniers Download PDF

Info

Publication number
EP2769985B1
EP2769985B1 EP14162246.4A EP14162246A EP2769985B1 EP 2769985 B1 EP2769985 B1 EP 2769985B1 EP 14162246 A EP14162246 A EP 14162246A EP 2769985 B1 EP2769985 B1 EP 2769985B1
Authority
EP
European Patent Office
Prior art keywords
seq
polypeptide
sequence
host cell
dicarboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP14162246.4A
Other languages
German (de)
English (en)
Other versions
EP2769985A1 (fr
Inventor
Amanda Fischer
Debbie Yaver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes Inc
Original Assignee
Novozymes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes Inc filed Critical Novozymes Inc
Publication of EP2769985A1 publication Critical patent/EP2769985A1/fr
Application granted granted Critical
Publication of EP2769985B1 publication Critical patent/EP2769985B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/38—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Aspergillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/44—Polycarboxylic acids
    • C12P7/46—Dicarboxylic acids having four or less carbon atoms, e.g. fumaric acid, maleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y604/00—Ligases forming carbon-carbon bonds (6.4)
    • C12Y604/01—Ligases forming carbon-carbon bonds (6.4.1)
    • C12Y604/01001—Pyruvate carboxylase (6.4.1.1)

Definitions

  • This application contains a reference to a deposit of biological material.
  • the present invention relates to polypeptides having C4-dicarboxylic acid transporter activity and polynucleotides encoding the polypeptides.
  • the invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, and methods of producing C4-dicarboxylic acids, such as malic acid.
  • Organic acids have a long history of commercial use in a variety of industries.
  • organic acids are used in the food and feed industries (citric acid, ascorbic acid, lactic acid, acetic acid, and gluconic acid) as monomers for the production of various polymers (adipic acid, lactic acid, acrylic acid, and itaconic acid), as metal chelators (gluconic acid), and as "green” solvents (acetic acid) ( Sauer et al., 2008, Trends in Biotechnology 26: 100-108 ).
  • Organic acids may themselves be commercial products or they may be chemical building blocks used in the manufacture of other chemicals.
  • C4-dicarboxylic acids can also serve as building block compounds for the production of large volume industrial chemicals, such as 1,4-butanediol, tetrahydrofuran, and gamma-butyrolactone.
  • large volume industrial chemicals such as 1,4-butanediol, tetrahydrofuran, and gamma-butyrolactone.
  • the cost of producing these large volume industrial chemicals by traditional petrochemical routes has increased significantly due to the high cost of petroleum derived building blocks.
  • Organic acids are produced commercially either by chemical synthesis from petroleum derived feedstocks (e.g., fumaric acid, malic acid, acrylic acid, and adipic acid) or by microbial fermentation (e.g., citric acid, lactic acid, gluconic acid, and itaconic acid).
  • Some organic acids such as fumaric acid and malic acid can also be produced by microbial fermentation, but are currently produced commercially by chemical synthesis from petrochemical feedstocks due to lower production costs.
  • the rising cost of petroleum derived building block chemicals, the geopolitical instability affecting crude oil prices, and the desire to implement manufacturing processes that utilize feedstocks derived from renewable resources have stimulated a renewed interest in producing organic acids and other chemicals by microbial fermentation.
  • WO 2008/144626 discloses malic acid production in recombinant yeast having a genetic modification that reduces pyruvate decarboxylase polypeptide activity. While malic acid is produced commercially today by chemical synthesis from petrochemical feedstocks, it can also be produced by microbial fermentation. Malic acid has been produced at high levels in genetically engineered yeast ( Saccharomyces cerevisiae ) ( Zelle et al., 2008, Appl. Environ. Microbiol. 74: 2766-2777 ) and naturally occurring filamentous fungi such as Aspergillus spp. ( U.S. Patent No. 3,063,910 ; Bercovitz et al., 1990, Appl. Environ. Microbiol.
  • the EMBL DATABSE, accession no. EED53359 disclose the sequence of a putative C4-dicarboxylate transporter/malic acid transport protein derived from Aspergillus flavus NRRL3357.
  • Malic acid overproduction in Aspergillus spp. occurs under specific culture conditions (aerobic conditions and high C:N ratio; calcium carbonate is also added as a neutralizing agent and as source of CO 2 for malic acid biosynthesis). Under these conditions, overflow metabolism via the cytosolic, reductive tricarboxylic acid (TCA) cycle results in increased malic acid biosynthesis and secretion into the culture medium. Increased malic acid production has been reported in Saccharomyces cerevisiae by increasing the level of pyruvate carboxylase ( Bauer et al., 1999, FEMS Microbiol Lett. 179: 107-113 ) or malate dehydrogenase ( Pines et al., 1997, Appl. Microbiol.
  • the present invention provides, inter alia, polypeptides having C4-dicarboxylic acid transporter activity, polynucleotides encoding the polypeptides, and methods for improving C4-dicarboxylic acid production (e.g., malic acid production).
  • the present invention relates to isolated polypeptides having C4-dicarboxylic acid transporter activity.
  • the isolated polypeptides having C4-dicarboxylic acid transporter activity are selected from: (a) a polypeptide having at least 80% sequence identity to SEQ ID NO: 4, or the mature polypeptide sequence thereof, wherein the mature polypeptide sequence of SEQ ID NO: 4 is amino acids 18 to 418 of SEQ ID NO: 4; (b) a polypeptide encoded by a polynucleotide that hybridizes under high stringency conditions with SEQ ID NO: 3, the mature polypeptide coding sequence thereof, wherein the mature polypeptide coding sequence of SEQ ID NO: 3 is nucleotides 52 to 1257 of SEQ ID NO: 3, or the full-length complementary strand of the foregoing; (c) a polypeptide encoded by a polynucleotide having at least 80% sequence identity to SEQ ID NO: 3, or the mature polypeptide coding sequence thereof, wherein the mature
  • the present invention also relates to methods of producing C4-dicarboxylic acids (e.g., malic acid).
  • the method comprises (a) cultivating a host cell (e.g., a filamentous fungal host cell) comprising a heterologous polynucleotide encoding a C4-dicarboxylic acid transporter described herein; and (b) recovering the C4-dicarboxylic acid (e.g., malic acid).
  • a host cell e.g., a filamentous fungal host cell
  • a heterologous polynucleotide encoding a C4-dicarboxylic acid transporter described herein
  • recovering the C4-dicarboxylic acid e.g., malic acid
  • the method comprises (a) transforming into host cell (e.g., a filamentous fungal host cell) a heterologous polynucleotide encoding a C4-dicarboxylic acid transporter described herein; (b) cultivating the transformed organism in a medium; and (c) recovering the C4-dicarboxylic acid (e.g., malic acid).
  • the host cell further comprises a heterologous polynucleotide encoding a malate dehydrogenase and/or a pyruvate carboxylase.
  • the present invention also relates to a host cell (e.g., a filamentous fungal host cell, such as Aspergillus oryzae ) comprising a heterologous polynucleotide encoding a C4-dicarboxylic acid transporter described herein wherein the host cell secretes and/or is capable of secreting increased levels of a C4-dicarboxylic acid (e.g., malic acid).
  • the host cell further comprises a heterologous polynucleotide encoding a malate dehydrogenase and/or a pyruvate carboxylase.
  • the present invention also relates to compositions comprising the polypeptides described herein, isolated polynucleotides encoding the polypeptides, nucleic acid constructs, expression vectors, recombinant host cells comprising the polynucleotides, and methods of producing the polypeptides.
  • C4-dicarboxylic acid transporter is defined herein as a dicarboxylic acid permease that can transport malic acid, succinic acid, oxaloacetic acid, malonic acid, and/or fumaric acid outside a cell ( Grobler et al., 1995, Yeast 11: 1485-1491 ; Camarasa et al., 2001, Applied and Environmental Microbiology 67: 4144-4151 ). A computational method to predict mitochondrially imported proteins and their targeting sequences is described by Claros and Vincens, 1996, Eur. J. Biochem. 241: 779-786 .
  • the C4-dicarboxylic acid transporters have at least 20%, e.g., at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% of the C4-dicarboxylic acid transporter activity (e.g., malic acid transporter activity) of the mature polypeptide SEQ ID NO: 4,.
  • the C4-dicarboxylic acid transporter activity e.g., malic acid transporter activity
  • malate dehydrogenase is defined herein as a malate:NAD + oxidoreductase (EC 1.1.1.37) that catalyzes the reduction of oxaloacetate in the presence of NADH + H + to malate and NAD + .
  • malate dehydrogenase activity is determined according to the following procedure.
  • the assay solution consists of 1 mM oxaloacetic acid, 100 mM Tris pH 8.0, 10 mM NaHCO 3 , 5 mM MgCl 2 , and 0.1 mM NADH (Sigma Chemical Co., St. Louis, MO, USA).
  • the assay solution without oxaloacetic acid as substrate is run as a control to measure background NADH degradation rates. Dilutions of 1/100, 1/500, 1/2500, and 1/12500 of each supernatant are prepared with double-distilled water. Aliquots of 270 ⁇ l of the assay solution are dispensed into 96 well polystyrene flat bottom plates. A 30 ⁇ l sample of each diluted supernatant is added to initiate the assay. The reactions are monitored using a SPECTRAMAX® 340PC plate reader (Molecular Devices, Sunnyvale, CA, USA) with the following settings: 340 nm, kinetic reading.
  • SPECTRAMAX® 340PC plate reader Molecular Devices, Sunnyvale, CA, USA
  • a concentration series of NADH is used to construct a standard curve and a dilution series of purified malic dehydrogenase (Sigma Chemical Co., St. Louis, MO, USA) is used as a positive control.
  • One unit of malate dehydrogenase activity equals the amount of enzyme capable of converting 1 ⁇ mole of oxaloacetate and NADH + H + to malate and NAD + per minute at pH 8.0, 25°C.
  • the malate dehydrogenases have at least 20%, e.g., at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% of the malate dehydrogenase activity of the mature polypeptide SEQ ID NO: 12.
  • Pyruvate carboxylase is defined herein as a pyruvate:carbon-dioxide ligase (ADP-forming) (EC 6.4.1.1) that catalyzes the carboxylation of pyruvate in the presence of ATP and HCO 3 - to oxaloacetate, ADP, and phosphate.
  • pyruvate carboxylase activity is determined according to the procedure of the SIGMA® Quality Control Test procedure for pyruvate carboxylase (Sigma Chemical Co., St. Louis, MO, USA) except the assay uses Tris buffer at pH 8.0.
  • One unit of pyruvate carboxylase activity equals the amount of enzyme capable of converting 1 ⁇ mole of pyruvate and CO 2 to oxaloacetate per minute at pH 7.8, 30°C.
  • the pyruvate carboxylases have at least 20%, e.g., at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% of the pyruvate carboxylase activity of the mature polypeptide SEQ ID NO: 16.
  • Heterologous polynucleotide is defined herein as a polynucleotide that is not native to the host cell; a native polynucleotide in which structural modifications have been made to the coding region; a native polynucleotide whose expression is quantitatively altered as a result of a manipulation of the DNA by recombinant DNA techniques, e.g., a different (foreign) promoter; or a native polynucleotide whose expression is quantitatively altered by the introduction of one or more (e.g., two, several) extra copies of the polynucleotide into the host cell.
  • Isolated/purified mean a polypeptide or polynucleotide that is removed from at least one component with which it is naturally associated.
  • a polypeptide may be at least 1% pure, e.g., at least 5% pure, at least 10% pure, at least 20% pure, at least 40% pure, at least 60% pure, at least 80% pure, at least 90% pure, at least 93% pure, at least 95% pure, at least 97%, at least 98% pure, or at least 99% pure, as determined by SDS-PAGE and a polynucleotide may be at least 1% pure, e.g., at least 5% pure, at least 10% pure, at least 20% pure, at least 40% pure, at least 60% pure, at least 80% pure, at least 90%, at least 93% pure, at least 95% pure, at least 97%, at least 98% pure, or at least 99% pure, as determined by agarose electrophoresis.
  • Coding sequence means a polynucleotide sequence, which specifies the amino acid sequence of a polypeptide.
  • the boundaries of the coding sequence are generally determined by an open reading frame, which usually begins with the ATG start codon or alternative start codons such as GTG and TTG and ends with a stop codon such as TAA, TAG, and TGA.
  • the coding sequence may be a sequence of genomic DNA, cDNA, a synthetic polynucleotide, and/or a recombinant polynucleotide.
  • cDNA sequence means a sequence of DNA following reverse transcription from a mature, spliced, mRNA molecule obtained from a eukaryotic cell.
  • the initial, primary RNA transcript from genomic DNA is a precursor to mRNA that is processed through a series of steps, including splicing, before appearing as mature spliced mRNA.
  • a cDNA sequence lacks intervening intron sequences that may be present in the corresponding genomic DNA sequence. Accordingly, the phrase "the cDNA sequence of SEQ ID NO: X" intends the resulting sequence after the intervening intron sequences of SEQ ID NO: X, if present, are removed. In some instances-when a referenced genomic DNA sequence lacks intervening intron sequences-a cDNA sequence may be identical to its corresponding genomic DNA sequence.
  • Genomic DNA sequence means a DNA sequence found in the genome of a source organism (e.g., a eukaryotic or prokaryotic genome).
  • a genomic DNA sequence from a eukaryotic genome contains one or more intervening intron sequences that are removed from the primary RNA transcript as a result of RNA splicing.
  • the phrase "the genomic DNA sequence of SEQ ID NO: Y" intends the corresponding DNA sequence from the source organism which includes intervening intron sequences, if any, that are present before RNA splicing.
  • Mature polypeptide sequence means the portion of the referenced polypeptide sequence after any post-translational sequence modifications (such as N-terminal processing and/or C-terminal truncation). In some instances, the mature polypeptide sequence may be identical to the entire referenced polypeptide sequence. In one aspect, the mature polypeptide sequence is amino acids 18 to 418 of SEQ ID NO: 4 based on the SignaIP program ( Nielsen et al., 1997, Protein Engineering 10: 1-6 ) that predicts amino acids 1 to 17 of SEQ ID NO: 4 are a signal peptide.
  • Mature polypeptide coding sequence means the portion of the referenced polynucleotide sequence (e.g., genomic or cDNA sequence) that encodes a mature polypeptide sequence. In some instances, the mature polypeptide coding sequence may be identical to the entire referenced polynucleotide sequence. In one aspect, the mature polypeptide coding sequence is nucleotides 52 to 1257 of SEQ ID NO: 3 based on the SignaIP program ( Nielsen et al., 1997, Protein Engineering 10: 1-6 ) that predicts nucleotides 1 to 51 of SEQ ID NO: 3 encode a signal peptide.
  • fragment means a polypeptide having one or more (e.g., two, several) amino acids deleted from the amino and/or carboxyl terminus of a referenced polypeptide sequence. In one aspect, the fragment has C4-dicarboxylic acid transporter activity. In another aspect, a fragment contains at least 355 amino acid residues, e.g., at least 375 amino acid residues or at least 395 amino acid residues of SEQ ID NO: 4. Subsequence: The term “subsequence” means a polynucleotide having one or more (e.g., two, several) nucleotides deleted from the 5' and/or 3' end of the referenced nucleotide sequence.
  • the subsequence encodes a fragment having C4-dicarboxylic acid transporter activity.
  • a subsequence contains at least 1065 nucleotides, e.g., at least 1125 nucleotides, or at least 1185 nucleotides of SEQ ID NO: 3.
  • Allelic variant means any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences.
  • An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.
  • Sequence Identity The relatedness between two amino acid sequences or between two nucleotide sequences is described by the parameter "sequence identity”.
  • the degree of sequence identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm ( Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453 ) as implemented in the Needle program of the EMBOSS package ( EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277 ), preferably version 3.0.0 or later.
  • the optional parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix.
  • the degree of sequence identity between two deoxyribonucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, supra ) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, supra ), preferably version 3.0.0 or later.
  • the optional parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix.
  • expression includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.
  • nucleic acid construct means a nucleic acid molecule-single-stranded or double-stranded-which is isolated from a naturally occurring gene, modified to contain segments of nucleic acids in a manner that would not otherwise exist in nature, or synthetic, wherein the nucleic acid molecule comprises one or more (e.g., two, several) control sequences.
  • control sequence means a nucleic acid sequence necessary for polypeptide expression.
  • Control sequences may be native or foreign to the polynucleotide encoding the polypeptide, and native or foreign to each other.
  • Such control sequences include, but are not limited to, a leader sequence, polyadenylation sequence, propeptide sequence, promoter sequence, signal peptide sequence, and transcription terminator sequence.
  • the control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the polynucleotide encoding a polypeptide.
  • operably linked means a configuration in which a control sequence is placed at an appropriate position relative to the coding sequence of a polynucleotide such that the control sequence directs the expression of the coding sequence.
  • Expression vector means a linear or circular DNA molecule that comprises a polynucleotide encoding a polypeptide and is operably linked to control sequences, wherein the control sequences provide for expression of the polynucleotide encoding the polypeptide.
  • the expression vector comprises a promoter sequence, and transcriptional and translational stop signal sequences.
  • host cell means any cell type that is susceptible to transformation, transfection, transduction, and the like with a nucleic acid construct or expression vector comprising a polynucleotide of the present invention (e.g., a polynucleotide encoding a C4-dicarboxylic acid transporter).
  • host cell encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication.
  • variant means a polypeptide having activity, e.g., C4-dicarboxylic acid transporter activity, comprising an alteration, i.e., a substitution, insertion, and/or deletion of one or more (e.g., two, several) amino acid residues at one or more positions.
  • a substitution means a replacement of an amino acid occupying a position with a different amino acid;
  • a deletion means removal of an amino acid occupying a position;
  • an insertion means adding one or more, e.g., 1-3 amino acids, adjacent to an amino acid occupying a position.
  • volumetric productivity refers to the amount of referenced product produced (e.g., the amount of a C4-dicarboxylic acid produced) per volume of the system used (e.g., the total volume of media and contents therein) per unit of time.
  • Fermentable medium refers to a medium comprising one or more (e.g., two, several) sugars, such as glucose, fructose, sucrose, cellobiose, xylose, xylulose, arabinose, mannose, galactose, and/or soluble oligosaccharides, wherein the medium is capable, in part, of being converted (fermented) by a host cell into a desired product, such as a C4-dicarboxylic acid.
  • the fermentation medium is derived from a natural source, such as sugar cane, starch, or cellulose, and may be the result of pretreating the source by enzymatic hydrolysis (saccharification).
  • references to "about” a value or parameter herein includes aspects that are directed to that value or parameter per se. For example, description referring to "about X” includes the aspect "X”.
  • the present invention relates to isolated polypeptides having C4-dicarboxylic acid transporter activity.
  • isolated polypeptides having C4-dicarboxylic acid transporter activity are selected from:
  • the isolated polypeptide has an amino acid sequence of at least 80%, e.g., at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%, sequence identity to SEQ ID NO: 4, or the mature polypeptide sequence thereof, which has C4-dicarboxylic acid transporter activity.
  • the polypeptide comprises an amino acid sequence that differs by no more than ten amino acids, e.g., by five amino acids, by four amino acids, by three amino acids, by two amino acids, or by one amino acid from SEQ ID NO: 4, or the mature polypeptide sequence thereof.
  • the polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 4, the mature polypeptide sequence of SEQ ID NO: 4, an allelic variant thereof, or a fragment of the foregoing, having C4-dicarboxylic acid transporter activity.
  • the polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 4.
  • the polypeptide comprises or consists of the mature polypeptide sequence of SEQ ID NO: 4.
  • the isolated polypeptides having C4-dicarboxylic acid transporter activity are encoded by polynucleotides that hybridize under high stringency conditions, or very high stringency conditions with SEQ ID NO: 3, the mature polypeptide coding sequence thereof, or the full-length complementary strand of the foregoing ( J. Sambrook, E.F. Fritsch, and T. Maniatis, 1989, Molecular Cloning, A Laboratory Manual, 2d edition, Cold Spring Harbor, New York ).
  • the isolated polypeptides having C4-dicarboxylic acid transporter activity are encoded by polynucleotides having at least 80%, e.g., at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 3 the mature polypeptide coding sequence thereof, or the full-length complementary strand of the foregoing.
  • the polypeptide is encoded by SEQ ID NO: 3 or the mature polypeptide coding sequence thereof. In one aspect, the polypeptide is encoded by SEQ ID NO: 3. In one aspect, the polypeptide is encoded by a subsequence of SEQ ID NO: 3, wherein the subsequence encodes a polypeptide having C4-dicarboxylic acid transporter activity.
  • the polypeptide is a variant comprising a substitution, deletion, and/or insertion of one or more amino acids of SEQ ID NO: 4. In one aspect, the polypeptide is a variant comprising a substitution, deletion, and/or insertion of one or more amino acids of the mature polypeptide sequence of SEQ ID NO: 4.
  • amino acid changes are of a minor nature, that is conservative amino acid substitutions or insertions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of one to about 30 amino acids; small amino-terminal or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to about 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.
  • conservative substitutions are within the group of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine and valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine, serine, threonine and methionine).
  • Amino acid substitutions that do not generally alter specific activity are known in the art and are described, for example, by H. Neurath and R.L. Hill, 1979, In, The Proteins, Academic Press, New York .
  • the most commonly occurring exchanges are Ala/Ser, Val/IIe, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly.
  • amino acid changes are of such a nature that the physico-chemical properties of the polypeptides are altered.
  • amino acid changes may improve the thermal stability of the polypeptide, alter the substrate specificity, change the pH optimum, and the like.
  • Essential amino acids in a parent polypeptide can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis ( Cunningham and Wells, 1989, Science 244: 1081-1085 ). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for C4-dicarboxylic acid transporter activity to identify amino acid residues that are critical to the activity of the molecule. See also, Hilton et al., 1996, J. Biol. Chem. 271: 4699-4708 .
  • the active site of the enzyme or other biological interaction can also be determined by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction, or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos et al., 1992, Science 255: 306-312 ; Smith et al., 1992, J. Mol. Biol. 224: 899-904 ; Wlodaver et al., 1992, FEBS Lett. 309: 59-64 .
  • the identities of essential amino acids can also be inferred from analysis of identities with polypeptides that are related to the parent polypeptide.
  • Single or multiple amino acid substitutions, deletions, and/or insertions can be made and tested using known methods of mutagenesis, recombination, and/or shuffling, followed by a relevant screening procedure, such as those disclosed by Reidhaar-Olson and Sauer, 1988, Science 241: 53-57 ; Bowie and Sauer, 1989, Proc. Natl. Acad. Sci. USA 86: 2152-2156 ; WO 95/17413 ; or WO 95/22625 .
  • Other methods that can be used include error-prone PCR, phage display (e.g., Lowman et al., 1991, Biochemistry 30: 10832-10837 ; U.S. Patent No. 5,223,409 ; WO 92/06204 ), and region-directed mutagenesis ( Derbyshire et al., 1986, Gene 46: 145 ; Ner et al., 1988, DNA 7: 127 ).
  • Mutagenesis/shuffling methods can be combined with high-throughput, automated screening methods to detect activity of cloned, mutagenized polypeptides expressed by host cells ( Ness et al., 1999, Nature Biotechnology 17: 893-896 ). Mutagenized DNA molecules that encode active polypeptides can be recovered from the host cells and rapidly sequenced using standard methods in the art. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide.
  • the total number of amino acid substitutions, deletions and/or insertions of SEQ ID NO: 4, or the mature polypeptide sequence thereof is not more than 10, e.g., not more than 1, 2, 3, 4, 5, 6, 7, 8 or 9.
  • polypeptide is a fragment of SEQ ID NO: 4 or the mature polypeptide sequence thereof, wherein the fragment has C4-dicarboxylic acid transporter activity.
  • the fragment contains at least 355 amino acid residues, e.g., at least 375 amino acid residues, or at least 395 amino acid residues of SEQ ID NO: 4.
  • the polypeptide may be a hybrid polypeptide in which a portion of one polypeptide is fused at the N-terminus or the C-terminus of a portion of another polypeptide.
  • the polypeptide may be a fused polypeptide or cleavable fusion polypeptide in which another polypeptide is fused at the N-terminus or the C-terminus of the polypeptide of the present invention.
  • a fused polypeptide is produced by fusing a polynucleotide encoding another polypeptide to a polynucleotide of the present invention.
  • Techniques for producing fusion polypeptides are known in the art, and include ligating the coding sequences encoding the polypeptides so that they are in frame and that expression of the fused polypeptide is under control of the same promoter(s) and terminator.
  • Fusion proteins may also be constructed using intein technology in which fusions are created post-translationally ( Cooper et al., 1993, EMBO J. 12: 2575-2583 ; Dawson et al., 1994, Science 266: 776-779 ).
  • a fusion polypeptide can further comprise a cleavage site between the two polypeptides. Upon secretion of the fusion protein, the site is cleaved releasing the two polypeptides.
  • cleavage sites include, but are not limited to, the sites disclosed in Martin et al., 2003, J. Ind. Microbiol. Biotechnol. 3: 568-576 ; Svetina et al., 2000, J. Biotechnol. 76: 245-251 ; Rasmussen-Wilson et al., 1997, Appl. Environ. Microbiol.
  • a polypeptide having C4-dicarboxylic acid transporter activity of the present invention may be obtained from microorganisms of any genus.
  • the term "obtained from” as used herein in connection with a given source shall mean that the polypeptide encoded by a polynucleotide is produced by the source or by a strain in which the polynucleotide from the source has been inserted.
  • the polypeptide obtained from a given source is secreted extracellularly.
  • the polypeptide may be a bacterial polypeptide.
  • the polypeptide may be a gram-positive bacterial polypeptide such as a Bacillus, Clostridium, Enterococcus, Geobacillus, Lactobacillus, Lactococcus, Oceanobacillus, Staphylococcus, Streptococcus, or Streptomyces polypeptide having C4-dicarboxylic acid transporter activity, or a gram-negative bacterial polypeptide such as a Campylobacter, E. coli, Flavobacterium, Fusobacterium, Helicobacter, Ilyobacter, Neisseria, Pseudomonas, Salmonella, or Ureaplasma polypeptide.
  • the polypeptide is a Bacillus alkalophilus, Bacillus amyloliquefaciens, Bacillus brevis, Bacillus circulans, Bacillus clausii, Bacillus coagulans, Bacillus firmus, Bacillus lautus, Bacillus lentus, Bacillus licheniformis, Bacillus megaterium, Bacillus pumilus, Bacillus stearothermophilus, Bacillus subtilis, or Bacillus thuringiensis polypeptide.
  • the polypeptide is a Streptococcus equisimilis, Streptococcus pyogenes, Streptococcus uberis, or Streptococcus equi subsp. Zooepidemicus polypeptide.
  • the polypeptide is a Streptomyces achromogenes, Streptomyces avermitilis, Streptomyces coelicolor, Streptomyces griseus, or Streptomyces lividans polypeptide.
  • the polypeptide may also be a fungal polypeptide.
  • the polypeptide may be a yeast polypeptide such as a Candida, Kluyveromyces, Pichia, Saccharomyces, Schizosaccharomyces, or Yarrowia polypeptide; or a filamentous fungal polypeptide such as an Acremonium, Agaricus, Alternaria, Aspergillus, Aureobasidium, Botryospaeria, Ceriporiopsis, Chaetomidium, Chrysosporium, Claviceps, Cochliobolus, Coprinopsis, Coptotermes, Corynascus, Cryphonectria, Cryptococcus, Diplodia, Exidia, Filibasidium, Fusarium, Gibberella, Holomastigotoides, Humicola, Irpex, Lentinula, Leptospaeria, Magnaporthe, Melanocarpus, Meripilus, Mucor, Myceliopht
  • the polypeptide is a Saccharomyces carlsbergensis, Saccharomyces cerevisiae, Saccharomyces diastaticus, Saccharomyces douglasii, Saccharomyces kluyveri, Saccharomyces norbensis, or Saccharomyces oviformis polypeptide.
  • the polypeptide is an Acremonium cellulolyticus, Aspergillus aculeatus, Aspergillus awamori, Aspergillus foetidus, Aspergillus fumigatus, Aspergillus japonicus, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Chrysosporium inops, Chrysosporium keratinophilum, Chrysosporium lucknowense, Chrysosporium merdarium, Chrysosporium pannicola, Chrysosporium queenslandicum, Chrysosporium tropicum, Chrysosporium zonatum, Fusarium bactridioides, Fusarium cerealis, Fusarium crookwellense, Fusarium culmorum, Fusarium graminearum, Fusarium graminum, Fusarium heterosporum, Fusa
  • the polypeptide is an Aspergillus polypeptide, e.g., an Aspergillus aculeatus polypeptide, such as an Aspergillus aculeatus polypeptide from E. coli NRRL B-50400, E. coli NRRL B-50388, or E. coli NRRL B-50401.
  • an Aspergillus polypeptide e.g., an Aspergillus aculeatus polypeptide, such as an Aspergillus aculeatus polypeptide from E. coli NRRL B-50400, E. coli NRRL B-50388, or E. coli NRRL B-50401.
  • polypeptide is an Aspergillus aculeatus polypeptide of SEQ ID NO: 4.
  • ATCC American Type Culture Collection
  • DSM Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
  • CBS Centraalbureau Voor Schimmelcultures
  • NRRL Northern Regional Research Center
  • the polypeptide may be identified and obtained from other sources including microorganisms isolated from nature (e.g., soil, composts, water, etc.) using the above-mentioned probes. Techniques for isolating microorganisms from natural habitats are well known in the art.
  • the polynucleotide encoding the polypeptide may then be obtained by similarly screening a genomic or cDNA library of another microorganism or mixed DNA sample.
  • the polynucleotide can be isolated or cloned by utilizing techniques that are well known to those of ordinary skill in the art (see, e.g., Sambrook et al., 1989, supra ).
  • the present invention also relates to isolated polynucleotides encoding a polypeptide of the present invention (e.g., an isolated polynucleotide encoding a polypeptide of any aspect related to SEQ ID NO: 4).
  • the techniques used to isolate or clone a polynucleotide encoding a polypeptide include isolation from genomic DNA, preparation from cDNA, or a combination thereof.
  • the cloning of the polynucleotides from such genomic DNA can be effected, e.g., by using the well known polymerase chain reaction (PCR) or antibody screening of expression libraries to detect cloned DNA fragments with shared structural features. See, e.g., Innis et al., 1990, PCR: A Guide to Methods and Application, Academic Press, New York .
  • nucleic acid amplification procedures such as ligase chain reaction (LCR), ligation activated transcription (LAT) and polynucleotide-based amplification (NASBA) may be used.
  • LCR ligase chain reaction
  • LAT ligation activated transcription
  • NASBA polynucleotide-based amplification
  • the polynucleotides may be cloned from a strain of Aspergillus (e.g., Aspergillus aculeatus ), or another or related organism and thus, for example, may be an allelic or species variant of the polypeptide encoding region of the nucleotide sequence.
  • the present invention also relates to an isolated polynucleotide comprising or consisting of at least 80%, e.g., at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%, sequence identity to SEQ ID NO: 3, or the mature polypeptide coding sequence thereof, which encodes a polypeptide having C4-dicarboxylic acid transporter activity.
  • Modification of a polynucleotide encoding a polypeptide of the present invention may be necessary for the synthesis of polypeptides substantially similar to the polypeptide.
  • the term "substantially similar" to the polypeptide refers to non-naturally occurring forms of the polypeptide.
  • These polypeptides may differ in some engineered way from the polypeptide isolated from its native source, e.g., variants that differ in specific activity, thermostability, pH optimum, or the like.
  • the variant may be constructed on the basis of the polynucleotide presented as the mature polypeptide coding sequence of SEQ ID NO: 3, e.g., a subsequence thereof, and/or by introduction of nucleotide substitutions that do not result in a change in the amino acid sequence of the polypeptide, but which correspond to the codon usage of the host organism intended for production of the enzyme, or by introduction of nucleotide substitutions that may give rise to a different amino acid sequence.
  • nucleotide substitution see, e.g., Ford et al., 1991, Protein Expression and Purification 2: 95-107 .
  • the present invention also relates to isolated polynucleotides encoding polypeptides of the present invention, which hybridize under high stringency conditions, or very high stringency conditions with SEQ ID NO: 3; the mature polypeptide coding sequence of SEQ ID NO: 3; the full-length complementary strand thereof; or an allelic variant or subsequence of the foregoing (Sambrook et al., 1989, supra), as defined herein.
  • the isolated polynucleotide hybridizes under high stringency conditions, or very high stringency conditions with SEQ ID NO: 3; the mature polypeptide coding sequence of SEQ ID NO: 3; the full-length complementary strand thereof; or an allelic variant or subsequence of the foregoing (Sambrook et al., 1989, supra), as defined herein.
  • the polynucleotide comprises or consists of SEQ ID NO: 3, the mature polypeptide coding sequence of SEQ ID NO: 3, or the sequence contained in plasmid pAaC4T521 which is contained in E. coli NRRL B-50388, or a subsequence of SEQ ID NO: 3 that encodes a fragment of SEQ ID NO: 4 having C4-dicarboxylic acid transporter activity (e.g., amino acids 18-418 of SEQ ID NO: 4), such as the polynucleotide of nucleotides 52 to 1257 of SEQ ID NO: 3.
  • C4-dicarboxylic acid transporter activity e.g., amino acids 18-418 of SEQ ID NO: 4
  • the polynucleotide of SEQ ID NO: 3, or a subsequence thereof; as well as the amino acid sequence of SEQ ID NO: 4, or a fragment thereof; may be used to design nucleic acid probes to identify and clone DNA encoding polypeptides having C4-dicarboxylic acid transporter activity from strains of different genera or species according to methods well known in the art.
  • such probes can be used for hybridization with the genomic or cDNA of the genus or species of interest, following standard Southern blotting procedures, in order to identify and isolate the corresponding gene therein.
  • Such probes can be considerably shorter than the entire sequence, but should be at least 14, e.g., at least 25, at least 35, or at least 70 nucleotides in length.
  • the nucleic acid probe is at least 100 nucleotides in length, e.g., at least 200 nucleotides, at least 300 nucleotides, at least 400 nucleotides, at least 500 nucleotides, at least 600 nucleotides, at least 700 nucleotides, at least 800 nucleotides, or at least 900 nucleotides in length.
  • Both DNA and RNA probes can be used.
  • the probes are typically labeled for detecting the corresponding gene (for example, with 32 P, 3 H, 35 S, biotin, or avidin). Such probes are encompassed by the present invention.
  • a genomic DNA or cDNA library prepared from such other strains may be screened for DNA that hybridizes with the probes described above and encodes a polypeptide having C4-dicarboxylic acid transporter activity.
  • Genomic or other DNA from such other strains may be separated by agarose or polyacrylamide gel electrophoresis, or other separation techniques.
  • DNA from the libraries or the separated DNA may be transferred to and immobilized on nitrocellulose or other suitable carrier material.
  • the carrier material is preferably used in a Southern blot.
  • hybridization indicates that the polynucleotide hybridizes to a labeled nucleic acid probe corresponding SEQ ID NO: 3; the mature polypeptide coding sequence of SEQ ID NO: 3; a full-length complementary strand thereof; or a subsequence of the foregoing; under very low to very high stringency conditions.
  • Molecules to which the nucleic acid probe hybridizes under these conditions can be detected using, for example, X-ray film.
  • the nucleic acid probe is SEQ ID NO: 3. In one aspect, the nucleic acid probe is the mature polypeptide coding sequence of SEQ ID NO: 3. In another aspect, the nucleic acid probe is a polynucleotide that encodes the polypeptide of SEQ ID NO: 4, or a fragment thereof. In another aspect, the nucleic acid probe is SEQ ID NO: 3. In another aspect, the nucleic acid probe is the polynucleotide contained in plasmid pAaC4T521 which is contained in E. coli NRRL B-50388, wherein the polynucleotide encodes a polypeptide having C4-dicarboxylic acid transporter activity.
  • the nucleic acid probe is the mature polypeptide coding sequence contained in plasmid pAaC4T521 which is contained in E. coli NRRL B-50388, wherein the polypeptide has C4-dicarboxylic acid transporter activity.
  • very low to very high stringency conditions are defined as prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and either 25% formamide for very low and low stringencies, 35% formamide for medium and medium-high stringencies, or 50% formamide for high and very high stringencies, following standard Southern blotting procedures for 12 to 24 hours optimally.
  • the carrier material is finally washed three times each for 15 minutes using 2X SSC, 0.2% SDS at 45°C (very low stringency), at 50°C (low stringency), at 55°C (medium stringency), at 60°C (medium-high stringency), at 65°C (high stringency), and at 70°C (very high stringency).
  • stringency conditions are defined as prehybridization and hybridization at about 5°C to about 10°C below the calculated T m using the calculation according to Bolton and McCarthy (1962, Proc. Natl. Acad. Sci. USA 48:1390 ) in 0.9 M NaCl, 0.09 M Tris-HCl pH 7.6, 6 mM EDTA, 0.5% NP-40, 1X Denhardt's solution, 1 mM sodium pyrophosphate, 1 mM sodium monobasic phosphate, 0.1 mM ATP, and 0.2 mg of yeast RNA per ml following standard Southern blotting procedures for 12 to 24 hours optimally. The carrier material is finally washed once in 6X SCC plus 0.1% SDS for 15 minutes and twice each for 15 minutes using 6X SSC at 5°C to 10°C below the calculated T m .
  • the present invention also relates to nucleic acid constructs comprising a polynucleotide of the present invention operably linked to one or more (e.g., two, several) control sequences that direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences.
  • the present invention also embraces recombinant host cells and methods utilizing nucleic acid constructs comprising a heterologous polynucleotide encoding a C4-dicarboxylic acid transporter described herein (and/or a malate dehydrogenase, or a pyruvate carboxylase described herein) linked to one or more control sequences that direct expression in a suitable host cell under conditions compatible with the control sequence(s).
  • Such nucleic acid constructs may be used in any of the host cells and methods describe herein.
  • polynucleotides described herein may be manipulated in a variety of ways to provide for expression of the polypeptide. Manipulation of the polynucleotide prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying polynucleotides utilizing recombinant DNA methods are well known in the art.
  • the control sequence may be a promoter sequence, a polynucleotide that is recognized by a host cell for expression of a polynucleotide encoding a polypeptide of the present invention.
  • the promoter sequence contains transcriptional control sequences that mediate the expression of the polypeptide.
  • the promoter may be any polynucleotide that shows transcriptional activity in the host cell of choice including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.
  • Each polynucleotide described herein may be operably linked to a promoter that is foreign to the polynucleotide.
  • the heterologous polynucleotide encoding a C4-dicarboxylic acid transporter is operably linked to a promoter that is foreign to the polynucleotide.
  • the heterologous polynucleotide encoding a malate dehydrogenase is operably linked to promoter foreign to the polynucleotide.
  • the heterologous polynucleotide encoding a pyruvate carboxylase is operably linked to promoter foreign to the polynucleotide.
  • suitable promoters for directing the transcription of the nucleic acid constructs of the present invention in a bacterial host cell are the promoters obtained from the Bacillus amyloliquefaciens alpha-amylase gene ( amyQ ), Bacillus licheniformis alpha-amylase gene ( amyL ), Bacillus licheniformis penicillinase gene ( penP ), Bacillus stearothermophilus maltogenic amylase gene ( amyM ), Bacillus subtilis levansucrase gene ( sacB ), Bacillus subtilis xylA and xylB genes, E.
  • amyQ Bacillus amyloliquefaciens alpha-amylase gene
  • amyL Bacillus licheniformis alpha-amylase gene
  • penP Bacillus licheniformis penicillinase gene
  • amyM Bacillus stearothermophilus maltogenic amylase gene
  • sacB Bacillus subtil
  • promoters for directing the transcription of the nucleic acid constructs of the present invention in a filamentous fungal host cell are promoters obtained from the genes for Aspergillus nidulans acetamidase, Aspergillus niger neutral alpha-amylase, Aspergillus niger acid stable alpha-amylase, Aspergillus niger or Aspergillus awamori glucoamylase ( glaA ), Aspergillus oryzae TAKA amylase, Aspergillus oryzae alkaline protease, Aspergillus oryzae triose phosphate isomerase, Fusarium oxysporum trypsin-like protease ( WO 96/00787 ), Fusarium venenatum amyloglucosidase ( WO 00/56900 ), Fusarium venenatum Daria ( WO 00/56900 ), Fusarium
  • useful promoters are obtained from the genes for Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae galactokinase (GAL1), Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH1, ADH2/GAP), Saccharomyces cerevisiae triose phosphate isomerase (TPI), Saccharomyces cerevisiae metallothionein (CUP1), and Saccharomyces cerevisiae 3-phosphoglycerate kinase.
  • ENO-1 Saccharomyces cerevisiae enolase
  • GAL1 Saccharomyces cerevisiae galactokinase
  • ADH1, ADH2/GAP Saccharomyces cerevisiae triose phosphate isomerase
  • TPI Saccharomyces cerevisiae metallothionein
  • the control sequence may also be a suitable transcription terminator sequence, which is recognized by a host cell to terminate transcription.
  • the terminator sequence is operably linked to the 3'-terminus of the polynucleotide encoding the polypeptide. Any terminator that is functional in the host cell of choice may be used in the present invention.
  • Preferred terminators for filamentous fungal host cells are obtained from the genes for Aspergillus nidulans anthranilate synthase, Aspergillus niger glucoamylase, Aspergillus niger alpha-glucosidase, Aspergillus oryzae TAKA amylase, and Fusarium oxysporum trypsin-like protease.
  • Preferred terminators for yeast host cells are obtained from the genes for Saccharomyces cerevisiae enolase, Saccharomyces cerevisiae cytochrome C (CYC1), and Saccharomyces cerevisiae glyceraldehyde-3-phosphate dehydrogenase.
  • Other useful terminators for yeast host cells are described by Romanos et al., 1992, supra.
  • the control sequence may also be a suitable leader sequence, when transcribed is a nontranslated region of an mRNA that is important for translation by the host cell.
  • the leader sequence is operably linked to the 5'-terminus of the polynucleotide encoding the polypeptide. Any leader sequence that is functional in the host cell of choice may be used.
  • Preferred leaders for filamentous fungal host cells are obtained from the genes for Aspergillus oryzae TAKA amylase and Aspergillus nidulans triose phosphate isomerase.
  • Suitable leaders for yeast host cells are obtained from the genes for Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae 3-phosphoglycerate kinase, Saccharomyces cerevisiae alpha-factor, and Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP).
  • ENO-1 Saccharomyces cerevisiae enolase
  • Saccharomyces cerevisiae 3-phosphoglycerate kinase Saccharomyces cerevisiae alpha-factor
  • Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase ADH2/GAP
  • the control sequence may also be a polyadenylation sequence, a sequence operably linked to the 3'-terminus of the polynucleotide and, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence that is functional in the host cell of choice may be used.
  • Preferred polyadenylation sequences for filamentous fungal host cells are obtained from the genes for Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, Fusarium oxysporum trypsin-like protease, and Aspergillus niger alpha-glucosidase.
  • yeast host cells Useful polyadenylation sequences for yeast host cells are described by Guo and Sherman, 1995, Mol. Cellular Biol. 15: 5983-5990 .
  • the control sequence may also be a signal peptide coding region that encodes a signal peptide linked to the N-terminus of a polypeptide and directs the polypeptide into the cell's secretory pathway.
  • the 5'-end of the coding sequence of the polynucleotide may inherently contain a signal peptide coding sequence naturally linked in translation reading frame with the segment of the coding sequence that encodes the polypeptide.
  • the 5'-end of the coding sequence may contain a signal peptide coding sequence that is foreign to the coding sequence.
  • the foreign signal peptide coding sequence may be required where the coding sequence does not naturally contain a signal peptide coding sequence.
  • the foreign signal peptide coding sequence may simply replace the natural signal peptide coding sequence in order to enhance secretion of the polypeptide.
  • any signal peptide coding sequence that directs the expressed polypeptide into the secretory pathway of a host cell of choice may be used.
  • Effective signal peptide coding sequences for bacterial host cells are the signal peptide coding sequences obtained from the genes for Bacillus NCIB 11837 maltogenic amylase, Bacillus licheniformis subtilisin, Bacillus licheniformis beta-lactamase, Bacillus stearothermophilus alpha-amylase, Bacillus stearothermophilus neutral proteases ( nprT, nprS, nprM ), and Bacillus subtilis prsA. Further signal peptides are described by Simonen and Palva, 1993, Microbiological Reviews 57: 109-137 .
  • Effective signal peptide coding sequences for filamentous fungal host cells are the signal peptide coding sequences obtained from the genes for Aspergillus niger neutral amylase, Aspergillus niger glucoamylase, Aspergillus oryzae TAKA amylase, Humicola insolens cellulase, Humicola insolens endoglucanase V, Humicola lanuginosa lipase, and Rhizomucor miehei aspartic proteinase.
  • Useful signal peptides for yeast host cells are obtained from the genes for Saccharomyces cerevisiae alpha-factor and Saccharomyces cerevisiae invertase. Other useful signal peptide coding sequences are described by Romanos et al., 1992, supra.
  • the control sequence may also be a propeptide coding sequence that encodes a propeptide positioned at the N-terminus of a polypeptide.
  • the resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases).
  • a propolypeptide is generally inactive and can be converted to an active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide.
  • the propeptide coding sequence may be obtained from the genes for Bacillus subtilis alkaline protease ( aprE ), Bacillus subtilis neutral protease ( nprT ), Myceliophthora thermophila laccase ( WO 95/33836 ), Rhizomucor miehei aspartic proteinase, and Saccharomyces cerevisiae alpha-factor.
  • the propeptide sequence is positioned next to the N-terminus of a polypeptide and the signal peptide sequence is positioned next to the N-terminus of the propeptide sequence.
  • regulatory systems that allow the regulation of the expression of the polypeptide relative to the growth of the host cell.
  • regulatory systems are those that cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound.
  • Regulatory systems in prokaryotic systems include the lac, tac, and trp operator systems.
  • yeast the ADH2 system or GAL1 system may be used.
  • filamentous fungi the Aspergillus niger glucoamylase promoter, Aspergillus oryzae TAKA alpha-amylase promoter, and Aspergillus oryzae glucoamylase promoter may be used.
  • regulatory sequences are those that allow for gene amplification.
  • these regulatory sequences include the dihydrofolate reductase gene that is amplified in the presence of methotrexate, and the metallothionein genes that are amplified with heavy metals.
  • the polynucleotide encoding the polypeptide would be operably linked with the regulatory sequence.
  • the present invention also relates to recombinant expression vectors comprising a polynucleotide of the present invention, a promoter, and transcriptional and translational stop signals.
  • the present invention also embraces recombinant host cells and methods utilizing recombinant expression vectors comprising a heterologous polynucleotide encoding a C4-dicarboxylic acid transporter (and/or a malate dehydrogenase or a pyruvate carboxylase); as well as a promoter; and transcriptional and translational stop signals.
  • Such recombinant expression vectors may be used in any of the host cells and methods described herein.
  • the various nucleotide and control sequences may be joined together to produce a recombinant expression vector that may include one or more (e.g., two, several) convenient restriction sites to allow for insertion or substitution of the polynucleotide encoding the polypeptide at such sites.
  • the polynucleotide may be expressed by inserting the polynucleotide or a nucleic acid construct comprising the sequence into an appropriate vector for expression.
  • the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression.
  • the recombinant expression vector may be any vector (e.g., a plasmid or virus) that can be conveniently subjected to recombinant DNA procedures and can bring about expression of the polynucleotide.
  • the choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced.
  • the vector may be a linear or closed circular plasmid.
  • each polynucleotide encoding a C4-dicarboxylic acid transporter, a malate dehydrogenase, and/or a pyruvate carboxylase described herein is contained on an independent vector. In one aspect, at least two of the polynucleotides are contained on a single vector. In one aspect, all the polynucleotides encoding the C4-dicarboxylic acid transporter, the malate dehydrogenase, and the pyruvate carboxylase are contained on a single vector.
  • the vector may be an autonomously replicating vector, i.e., a vector that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome.
  • the vector may contain any means for assuring self-replication.
  • the vector may be one that, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated.
  • a single vector or plasmid or two or more vectors or plasmids that together contain the total DNA to be introduced into the genome of the host cell, or a transposon may be used.
  • the vector preferably contains one or more (e.g., two, several) selectable markers that permit easy selection of transformed, transfected, transduced, or the like cells.
  • a selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like.
  • bacterial selectable markers are the dal genes from Bacillus subtilis or Bacillus licheniformis, or markers that confer antibiotic resistance such as ampicillin, chloramphenicol, kanamycin, or tetracycline resistance.
  • Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3.
  • Selectable markers for use in a filamentous fungal host cell include, but are not limited to, amdS (acetamidase), argB (ornithine carbamoyltransferase), bar (phosphinothricin acetyltransferase), hph (hygromycin phosphotransferase), niaD (nitrate reductase), pyrG (orotidine-5'-phosphate decarboxylase), sC (sulfate adenyltransferase), and trpC (anthranilate synthase), as well as equivalents thereof.
  • Preferred for use in an Aspergillus cell are the amdS and pyrG genes of Aspergillus nidulans or Aspergillus oryzae and the bar gene of Streptomyces hygroscopicus.
  • the vector preferably contains an element(s) that permits integration of the vector into the host cell's genome or autonomous replication of the vector in the cell independent of the genome.
  • the vector may rely on the polynucleotide's sequence encoding the polypeptide or any other element of the vector for integration into the genome by homologous or non-homologous recombination.
  • the vector may contain additional polynucleotides for directing integration by homologous recombination into the genome of the host cell at a precise location(s) in the chromosome(s).
  • the integrational elements should contain a sufficient number of nucleic acids, such as 100 to 10,000 base pairs, 400 to 10,000 base pairs, and 800 to 10,000 base pairs, which have a high degree of sequence identity to the corresponding target sequence to enhance the probability of homologous recombination.
  • the integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding polynucleotides. On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination.
  • the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question.
  • the origin of replication may be any plasmid replicator mediating autonomous replication that functions in a cell.
  • the term "origin of replication" or "plasmid replicator” means a polynucleotide that enables a plasmid or vector to replicate in vivo.
  • bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permitting replication in E. coli, and pUB110, pE194, pTA1060, and pAMß1 permitting replication in Bacillus.
  • origins of replication for use in a yeast host cell are the 2 micron origin of replication, ARS1, ARS4, the combination of ARS1 and CEN3, and the combination of ARS4 and CEN6.
  • AMA1 and ANS1 examples of origins of replication useful in a filamentous fungal cell are AMA1 and ANS1 ( Gems et al., 1991, Gene 98: 61-67 ; Cullen et al., 1987, Nucleic Acids Res. 15: 9163-9175 ; WO 00/24883 ). Isolation of the AMA1 gene and construction of plasmids or vectors comprising the gene can be accomplished according to the methods disclosed in WO 00/24883 .
  • More than one copy of a polynucleotide of the present invention may be inserted into a host cell to increase production of a polypeptide.
  • An increase in the copy number of the polynucleotide can be obtained by integrating at least one additional copy of the sequence into the host cell genome or by including an amplifiable selectable marker gene with the polynucleotide where cells containing amplified copies of the selectable marker gene, and thereby additional copies of the polynucleotide, can be selected for by cultivating the cells in the presence of the appropriate selectable agent.
  • the host cells have malate dehydrogenase activity.
  • the host cells comprise a heterologous polynucleotide encoding a malate dehydrogenase.
  • the malate dehydrogenase can be any malate dehydrogenase that is suitable for practicing the invention.
  • the malate dehydrogenase is an enzyme that is present in the cytosol of the host cell.
  • the malate dehydrogenase is (a) a malate dehydrogenase having at least 60% sequence identity to SEQ ID NO: 12 or the mature polypeptide sequence thereof; (b) a malate dehydrogenase encoded by a polynucleotide that hybridizes under low stringency conditions with (i) SEQ ID NO: 11 or the mature polypeptide coding sequence thereof, (ii) the cDNA sequence of SEQ ID NO: 11 or the mature polypeptide coding sequence thereof, or (iii) the full-length complementary strand of (i) or (ii); (c) a malate dehydrogenase encoded by a polynucleotide having at least 60% sequence identity to (iv) SEQ ID NO: 11 or the mature polypeptide coding sequence thereof, (v) the cDNA sequence of SEQ ID NO: 11 or the mature polypeptide coding sequence thereof; or (vi) the full-length complementary
  • the malate dehydrogenase comprises or consists of an amino acid sequence having at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 12 or the mature polypeptide sequence thereof.
  • the malate dehydrogenase comprises an amino acid sequence that differs by no more than ten amino acids, e.g., by no more than five amino acids, by no more than four amino acids, by no more than three amino acids, by no more than two amino acids, or by one amino acid from SEQ ID NO: 12 or the mature polypeptide sequence thereof.
  • the malate dehydrogenase comprises or consists of the amino acid sequence of SEQ ID NO: 12, the mature polypeptide sequence of SEQ ID NO: 12, an allelic variant thereof, or a fragment of the foregoing, having malate dehydrogenase activity.
  • the malate dehydrogenase comprises or consists of the amino acid sequence of SEQ ID NO: 12.
  • the malate dehydrogenase comprises or consists of the mature polypeptide sequence of SEQ ID NO: 12.
  • the malate dehydrogenase comprises or consists of amino acids 1 to 330 of SEQ ID NO: 12.
  • the malate dehydrogenase is encoded by a polynucleotide that hybridizes under at least low stringency conditions, e.g., medium stringency conditions, medium-high stringency conditions, high stringency conditions, or very high stringency conditions with (i) SEQ ID NO: 11 or the mature polypeptide coding sequence thereof, (ii) the cDNA sequence of SEQ ID NO: 11 or the mature polypeptide coding sequence thereof, or (iii) the full-length complementary strand of (i) or (ii) (J. Sambrook, E.F. Fritsch, and T. Maniatis, 1989, supra).
  • the malate dehydrogenase is encoded by a polynucleotide having at least 65%, e.g., at least 70%, at least 75%, at least 80%, at least 85%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to (iv) SEQ ID NO: 11 or the mature polypeptide coding sequence thereof, (v) the cDNA sequence of SEQ ID NO: 11 or the mature polypeptide coding sequence thereof; or (vi) the full-length complementary strand of (iv) or (v).
  • the malate dehydrogenase is encoded by SEQ ID NO: 11, or the mature polypeptide coding sequence thereof. In one aspect, the malate dehydrogenase is encoded by SEQ ID NO: 11. In one aspect, the malate dehydrogenase is encoded by the mature polypeptide coding sequence of SEQ ID NO: 11. In one aspect, the malate dehydrogenase is encoded by a subsequence of SEQ ID NO: 11, wherein the subsequence encodes a polypeptide having malate dehydrogenase activity. In one aspect, the subsequence contains at least 885 nucleotides, e.g., at least 930 nucleotides or at least 975 nucleotides of SEQ ID NO: 11.
  • the malate dehydrogenase is a variant comprising a substitution, deletion, and/or insertion of one or more (e.g., two, several) amino acids of SEQ ID NO: 12, or the mature polypeptide sequence thereof, as described supra. In one aspect, the malate dehydrogenase is a variant comprising a substitution, deletion, and/or insertion of one or more amino acids of SEQ ID NO: 12. In one aspect, the malate dehydrogenase is a variant comprising a substitution, deletion, and/or insertion of one or more amino acids of the mature polypeptide sequence of SEQ ID NO: 12.
  • the total number of amino acid substitutions, deletions and/or insertions of the mature polypeptide sequence of SEQ ID NO: 12 or the mature polypeptide sequence thereof is not more than 10, e.g., not more than 1, 2, 3, 4, 5, 6, 7, 8 or 9.
  • the malate dehydrogenase is a fragment of SEQ ID NO: 12, or the mature polypeptide sequence thereof, wherein the fragment has malate dehydrogenase activity.
  • the fragment contains at least 295 amino acid residues, e.g., at least 310 amino acid residues, or at least 325 amino acid residues of SEQ ID NO: 12.
  • the malate dehydrogenase may also be an allelic variant or artificial variant of a malate dehydrogenase.
  • the malate dehydrogenase can also include fused polypeptides or cleavable fusion polypeptides, as described supra.
  • the polynucleotide of SEQ ID NO: 11; or a subsequence thereof; as well as the amino acid sequence of SEQ ID NO: 12; or a fragment thereof; may be used to design nucleic acid probes to identify and clone DNA encoding malate dehydrogenases from strains of different genera or species, as described supra. Such probes are encompassed by the present invention.
  • a genomic DNA or cDNA library prepared from such other organisms may be screened for DNA that hybridizes with the probes described above and encodes a malate dehydrogenase, as described supra.
  • the nucleic acid probe is SEQ ID NO: 11. In another aspect, the nucleic acid probe is the mature polypeptide coding sequence of SEQ ID NO: 11. In another aspect, the nucleic acid probe is a polynucleotide sequence that encodes SEQ ID NO: 12, the mature polypeptide sequence thereof, or a fragment of the foregoing.
  • the malate dehydrogenase may be obtained from microorganisms of any genus.
  • the malate dehydrogenase may be a bacterial, a yeast, or a filamentous fungal malate dehydrogenase obtained from the microorganisms described herein.
  • the malate dehydrogenase is an Aspergillus oryzae malate dehydrogenase, e.g., the Aspergillus oryzae malate dehydrogenase of SEQ ID NO: 12.
  • malate dehydrogenases that can be used to practice the present invention include, but are not limited to, a Aspergillus nidulans malate dehydrogenase (AN6717.1; SIMS et al., 2004, Mycol. Res.
  • the malate dehydrogenase is (a) a malate dehydrogenase having at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 20, or the mature polypeptide sequence thereof; (b) a malate dehydrogenase encoded by a polynucleotide that hybridizes under low stringency conditions, e.g., medium stringency conditions, medium-high stringency conditions, high stringency conditions, or very high stringency
  • low stringency conditions e.g., medium stringency conditions, medium-high stringency conditions, high stringency conditions, or very high stringency
  • the malate dehydrogenase may also be identified and obtained from other sources including microorganisms isolated from nature (e.g., soil, composts, water, etc.) or DNA samples obtained directly from natural materials (e.g., soil, composts, water, etc,) as described supra.
  • the host cells have pyruvate carboxylase activity.
  • the host cells comprise a heterologous polynucleotide encoding a pyruvate carboxylase.
  • the pyruvate carboxylase can be any pyruvate carboxylase that is suitable for practicing the invention.
  • the pyruvate carboxylase is an enzyme that is present in the cytosol of the host cell.
  • the pyruvate carboxylase is (a) a pyruvate carboxylase having at least 60% sequence identity to SEQ ID NO: 16 or the mature polypeptide sequence thereof; (b) a pyruvate carboxylase encoded by a polynucleotide that hybridizes under low stringency conditions with (i) SEQ ID NO: 15 or the mature polypeptide coding sequence thereof, (ii) the cDNA sequence of SEQ ID NO: 15 or the mature polypeptide coding sequence thereof, or (iii) the full-length complementary strand of (i) or (ii); (c) a pyruvate carboxylase encoded by a polynucleotide having at least 60% sequence identity to (iv) SEQ ID NO: 15 or the mature polypeptide coding sequence thereof, (v) the cDNA sequence of SEQ ID NO: 15 or the mature polypeptide coding sequence thereof; or (vi) the full-length complementary
  • the pyruvate carboxylase comprises or consists of an amino acid sequence having at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 16, or the mature polypeptide sequence thereof.
  • the pyruvate carboxylase comprises an amino acid sequence that differs by no more than ten amino acids, e.g., by no more than five amino acids, by no more than four amino acids, by no more than three amino acids, by no more than two amino acids, or by one amino acid from SEQ ID NO: 16 or the mature polypeptide sequence thereof.
  • the pyruvate carboxylase comprises or consists of the amino acid sequence of SEQ ID NO: 16, the mature polypeptide sequence of SEQ ID NO: 16, an allelic variant thereof, or a fragment of the foregoing, having pyruvate carboxylase activity.
  • the pyruvate carboxylase comprises or consists of the amino acid sequence of SEQ ID NO: 16.
  • the pyruvate carboxylase comprises or consists of the mature polypeptide sequence of SEQ ID NO: 16.
  • the pyruvate carboxylase comprises or consists of amino acids 1 to 1193 of SEQ ID NO: 16.
  • the pyruvate carboxylase is encoded by a polynucleotide that hybridizes under at least low stringency conditions, e.g., medium stringency conditions, medium-high stringency conditions, high stringency conditions, or very high stringency conditions with (i) SEQ ID NO: 15 or the mature polypeptide coding sequence thereof, (ii) the cDNA sequence of SEQ ID NO: 15 or the mature polypeptide coding sequence thereof, or (iii) the full-length complementary strand of (i) or (ii) (J. Sambrook, E.F. Fritsch, and T. Maniatis, 1989, supra).
  • the pyruvate carboxylase is encoded by a polynucleotide having at least 65%, e.g., at least 70%, at least 75%, at least 80%, at least 85%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to (iv) SEQ ID NO: 15 or the mature polypeptide coding sequence thereof, (v) the cDNA sequence of SEQ ID NO: 15 or the mature polypeptide coding sequence thereof; or (vi) the full-length complementary strand of (iv) or (v).
  • the pyruvate carboxylase is encoded by SEQ ID NO: 15 or the mature polypeptide coding sequence thereof. In one aspect, the pyruvate carboxylase is encoded by SEQ ID NO: 15. In one aspect, the pyruvate carboxylase is encoded by the mature polypeptide coding sequence of SEQ ID NO: 15. In one aspect, the pyruvate carboxylase is encoded by a subsequence of SEQ ID NO: 15, wherein the subsequence encodes a polypeptide having pyruvate carboxylase activity. In one aspect, the subsequence contains at least 3060 nucleotides, e.g., at least 3240 nucleotides or at least 3420 nucleotides of SEQ ID NO: 15.
  • the pyruvate carboxylase is a variant comprising a substitution, deletion, and/or insertion of one or more (e.g., two, several) amino acids of SEQ ID NO: 16, or the mature polypeptide sequence thereof, as described supra.
  • the pyruvate carboxylase is a variant comprising a substitution, deletion, and/or insertion of one or more amino acids of SEQ ID NO: 16.
  • the pyruvate carboxylase is a variant comprising a substitution, deletion, and/or insertion of one or more amino acids of the mature polypeptide sequence of SEQ ID NO: 16.
  • the total number of amino acid substitutions, deletions and/or insertions of SEQ ID NO: 16 or the mature polypeptide sequence thereof is not more than 16, e.g., not more than 1, 2, 3, 4, 5, 6, 7, 8 or 9.
  • the pyruvate carboxylase is a fragment of SEQ ID NO: 16, or the mature polypeptide sequence thereof, wherein the fragment has pyruvate carboxylase activity.
  • the fragment contains at least 1020 amino acid residues, e.g., at least 1080 amino acid residues, or at least 1140 amino acid residues of SEQ ID NO: 16.
  • the pyruvate carboxylase may also be an allelic variant or artificial variant of a pyruvate carboxylase.
  • the pyruvate carboxylase can also include fused polypeptides or cleavable fusion polypeptides, as described supra.
  • the pyruvate carboxylase can also be a variant of a mitochondrial pyruvate carboxylase, such that in vivo importation into the mitochondria is reduced thereby increasing the level of the pyruvate carboxylase variant in the cytosol.
  • the polynucleotide of SEQ ID NO: 15 or a subsequence thereof, as well as the amino acid sequence of SEQ ID NO: 16 or a fragment thereof, may be used to design nucleic acid probes to identify and clone DNA encoding pyruvate carboxylases from strains of different genera or species, as described supra. Such probes are encompassed by the present invention.
  • a genomic DNA or cDNA library prepared from such other organisms may be screened for DNA that hybridizes with the probes described above and encodes a pyruvate carboxylase, as described supra.
  • the nucleic acid probe is SEQ ID NO: 15. In another aspect, the nucleic acid probe is the mature polypeptide coding sequence of SEQ ID NO: 15. In another aspect, the nucleic acid probe is a polynucleotide sequence that encodes SEQ ID NO: 16, the mature polypeptide sequence thereof, or a fragment of the foregoing.
  • the pyruvate carboxylase may be obtained from microorganisms of any genus.
  • the pyruvate carboxylase may be a bacterial, a yeast, or a filamentous fungal pyruvate carboxylase obtained from the microorganisms described herein.
  • the pyruvate carboxylase is an Aspergillus oryzae pyruvate carboxylase, e.g., the Aspergillus oryzae pyruvate carboxylase of SEQ ID NO: 16.
  • the pyruvate carboxylase may also be identified and obtained from other sources including microorganisms isolated from nature (e.g., soil, composts, water, etc.) or DNA samples obtained directly from natural materials (e.g., soil, composts, water, etc,) as described supra.
  • the present invention also relates to recombinant host cells comprising a polynucleotide described herein operably linked to one or more (e.g., two, several) control sequences that direct the production of a polypeptides described herein.
  • the invention also embraces recombinant host cells comprising one or more polynucleotide(s) described herein which may be operably linked to one or more control sequences that direct the expression of one or more of the described polypeptides for the recombinant production of a C4-dicarboxylic acid, as well as methods of using such host cells for the production of a C4-dicarboxylic acid.
  • the host cell may comprise any one or combination of a plurality of the polynucleotides described.
  • the recombinant host cell comprises a heterologous polynucleotide encoding a C4-dicarboxylic acid transporter; and optionally comprises a heterologous polynucleotide encoding a heterologous polynucleotide encoding a malate dehydrogenase, and/or a heterologous polynucleotide encoding pyruvate decarboxylase; wherein the host cell produces (or is capable of producing) a greater amount of a C4-dicarboxylic acid compared to the host cell without the heterologous polynucleotide encoding the C4-dicarboxylic acid transporter when cultivated under the same conditions.
  • the recombinant host cell comprises:
  • the host cell comprises a heterologous polynucleotide encoding a C4-dicarboxylic acid transporter described herein (e.g., SEQ ID NO: 3, or any described aspect thereof) and a heterologous polynucleotide encoding a malate dehydrogenase.
  • the malate dehydrogenase can be any malate dehydrogenase that is suitable for practicing the present invention, as described supra.
  • the host cell comprises a heterologous polynucleotide encoding a C4-dicarboxylic acid transporter described herein (e.g., SEQ ID NO: 3, or any described aspect thereof) and a heterologous polynucleotide encoding a pyruvate carboxylase.
  • the pyruvate carboxylase can be any pyruvate carboxylase that is suitable for practicing the present invention, as described supra.
  • the pyruvate carboxylase is preferably an enzyme that is present in the cytosol of the host cell.
  • the host cell comprises a heterologous polynucleotide encoding a C4-dicarboxylic acid transporter described herein (e.g., SEQ ID NO: 3, or any described aspect thereof), a second heterologous polynucleotide encoding a malate dehydrogenase, and a third heterologous polynucleotide encoding a pyruvate carboxylase.
  • a heterologous polynucleotide encoding a C4-dicarboxylic acid transporter described herein (e.g., SEQ ID NO: 3, or any described aspect thereof), a second heterologous polynucleotide encoding a malate dehydrogenase, and a third heterologous polynucleotide encoding a pyruvate carboxylase.
  • a construct or vector comprising the one or more (e.g., two, several) polynucleotide(s) is introduced into a host cell so that the construct or vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector as described earlier.
  • the term "host cell” encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication. The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source. The aspects described below apply to the host cells, per se , as well as methods using the host cells.
  • the host cell may be any cell capable of the recombinant production of a polypeptide of the present invention, e.g., a prokaryote or a eukaryote, and/or any cell (e.g., any filamentous fungal cell) capable of the recombinant production of a C4-dicarboxylic acid (e.g., malic acid).
  • a polypeptide of the present invention e.g., a prokaryote or a eukaryote
  • any cell e.g., any filamentous fungal cell capable of the recombinant production of a C4-dicarboxylic acid (e.g., malic acid).
  • the prokaryotic host cell may be any gram-positive or gram-negative bacterium.
  • Gram-positive bacteria include, but not limited to, Bacillus, Clostridium, Enterococcus, Geobacillus, Lactobacillus, Lactococcus, Oceanobacillus, Staphylococcus, Streptococcus, and Streptomyces.
  • Gram-negative bacteria include, but not limited to, Campylobacter, E. coli, Flavobacterium, Fusobacterium, Helicobacter, Ilyobacter, Neisseria, Pseudomonas, Salmonella, and Ureaplasma.
  • the bacterial host cell may be any Bacillus cell including, but not limited to, Bacillus alkalophilus, Bacillus amyloliquefaciens, Bacillus brevis, Bacillus circulans, Bacillus clausii, Bacillus coagulans, Bacillus firmus, Bacillus lautus, Bacillus lentus, Bacillus licheniformis, Bacillus megaterium, Bacillus pumilus, Bacillus stearothermophilus, Bacillus subtilis, and Bacillus thuringiensis cells.
  • the bacterial host cell may also be any Streptococcus cell including, but not limited to, Streptococcus equisimilis, Streptococcus pyogenes, Streptococcus uberis, and Streptococcus equi subsp. Zooepidemicus cells.
  • the bacterial host cell may also be any Streptomyces cell including, but not limited to, Streptomyces achromogenes, Streptomyces avermitilis, Streptomyces coelicolor, Streptomyces griseus, and Streptomyces lividans cells.
  • the introduction of DNA into a Bacillus cell may, for instance, be effected by protoplast transformation (see, e.g., Chang and Cohen, 1979, Mol. Gen. Genet. 168: 111-115 ), by using competent cells (see, e.g., Young and Spizizen, 1961, J. Bacteriol. 81: 823-829 , or Dubnau and Davidoff-Abelson, 1971, J. Mol. Biol. 56: 209-221 ), by electroporation (see, e.g., Shigekawa and Dower, 1988, Biotechniques 6: 742-751 ), or by conjugation (see, e.g., Koehler and Thorne, 1987, J. Bacteriol.
  • the introduction of DNA into an E . coli cell may, for instance, be effected by protoplast transformation (see, e.g., Hanahan, 1983, J. Mol. Biol. 166: 557-580 ) or electroporation (see, e.g., Dower et al., 1988, Nucleic Acids Res. 16: 6127-6145 ).
  • the introduction of DNA into a Streptomyces cell may, for instance, be effected by protoplast transformation and electroporation (see, e.g., Gong et al., 2004, Folia Microbiol.
  • Pseudomonas cell may, for instance, be effected by electroporation (see, e.g., Choi et al., 2006, J. Microbiol. Methods 64: 391-397 ) or by conjugation (see, e.g., Pinedo and Smets, 2005, Appl.
  • the introduction of DNA into a Streptococcus cell may, for instance, be effected by natural competence (see, e.g., Perry and Kuramitsu, 1981, Infect. Immun. 32: 1295-1297 ), by protoplast transformation (see, e.g., Catt and Jollick, 1991, Microbios 68: 189-207 , by electroporation (see, e.g., Buckley et al., 1999, Appl. Environ. Microbiol. 65: 3800-3804 ) or by conjugation (see, e.g., Clewell, 1981, Microbiol. Rev. 45: 409-436 ).
  • any method known in the art for introducing DNA into a host cell can be used.
  • the host cell may also be a eukaryote, such as a mammalian, insect, plant, or fungal cell.
  • the host cell may be a fungal cell.
  • "Fungi” as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth et al., In, Ainsworth and Bisby's Dictionary of The Fungi, 8th edition, 1995, CAB International, University Press, Cambridge, UK ) as well as the Oomycota (as cited in Hawksworth et al., 1995, supra, page 171) and all mitosporic fungi (Hawksworth et al., 1995, supra).
  • the fungal host cell may be a yeast cell.
  • yeast as used herein includes ascosporogenous yeast (Endomycetales), basidiosporogenous yeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes). Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in Biology and Activities of Yeast (Skinner, F.A., Passmore, S.M., and Davenport, R.R., eds, Soc. App. Bacteriol. Symposium Series No. 9, 1980).
  • the yeast host cell may be a Candida, Hansenula, Kluyveromyces, Pichia, Saccharomyces, Schizosaccharomyces, or Yarrowia cell such as a Kluyveromyces lactis, Saccharomyces carlsbergensis, Saccharomyces cerevisiae, Saccharomyces diastaticus, Saccharomyces douglasii, Saccharomyces kluyveri, Saccharomyces norbensis, Saccharomyces oviformis , or Yarrowia lipolytica cell.
  • the fungal host cell may be a filamentous fungal cell.
  • "Filamentous fungi” include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, supra).
  • the filamentous fungi are generally characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as Saccharomyces cerevisiae is by budding of a unicellular thallus and carbon catabolism may be fermentative.
  • the filamentous fungal host cell may be an Acremonium, Aspergillus, Aureobasidium, Bjerkandera, Ceriporiopsis, Chrysosporium, Coprinus, Coriolus, Cryptococcus, Filibasidium, Fusarium, Humicola, Magnaporthe, Mucor, Myceliophthora, Neocallimastix, Neurospora, Paecilomyces, Penicillium, Phanerochaete, Phlebia, Piromyces, Pleurotus, Schizophyllum, Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trametes, or Trichoderma cell.
  • the filamentous fungal host cell may be an Aspergillus aculeatus, Aspergillus awamori, Aspergillus foetidus, Aspergillus fumigatus, Aspergillus japonicus, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Bjerkandera adusta, Ceriporiopsis aneirina, Ceriporiopsis caregiea, Ceriporiopsis gilvescens, Ceriporiopsis pannocinta, Ceriporiopsis rivulosa, Ceriporiopsis subrufa, Ceriporiopsis subvermispora, Chrysosporium inops, Chrysosporium keratinophilum , Chrysosporium lucknowense , Chrysosporium merdarium, Chrysosporium pannicola , Chrysosporium queenslandicum , Chryss
  • the host cell is an Aspergillus host cell. In another aspect, the host cell is Aspergillus oryzae .
  • Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known per se. Suitable procedures for transformation of Aspergillus and Trichoderma host cells are described in EP 238023 and Yelton et al., 1984, Proc. Natl. Acad. Sci. USA 81: 1470-1474 . Suitable methods for transforming Fusarium species are described by Malardier et al., 1989, Gene 78: 147-156 , and WO 96/00787 . Yeast may be transformed using the procedures described by Becker and Guarente, In Abelson, J.N.
  • the host cell comprises one or more (e.g., two, several) polynucleotide(s) described herein, wherein the host cell secretes (and/or is capable of secreting) an increased level of C4-dicarboxylic acid compared to the host cell without the one or more polynucleotide(s) when cultivated under the same conditions.
  • the host cell secretes (and/or is capable of secreting) an increased level of C4-dicarboxylic acid compared to the host cell without the one or more polynucleotide(s) when cultivated under the same conditions.
  • the host cell secretes and/or is capable of secreting an increased level of C4-dicarboxylic acid (e.g., malic acid) of at least 5%, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 50%, at least 100%, at least 150%, at least 200%, at least 300%, or at 500% compared to the host cell without the one or more polynucleotide(s) (e.g., without the heterologous polynucleotide encoding a C4-dicarboxylic acid transporter), when cultivated under the same conditions.
  • C4-dicarboxylic acid e.g., malic acid
  • the C4-dicarboxylic acid may be malic acid, succinic acid, oxaloacetic acid, malonic acid, or fumaric acid, or combinations thereof. In some aspects, the C4-dicarboxylic acid is malic acid, succinic acid, or fumaric acid, or combinations thereof. In some aspects, the C4-dicarboxylic acid is malic acid or fumaric acid, or a combination of malic acid and fumaric acid. In some aspects, the C4-dicarboxylic acid is malic acid.
  • the host cell produces (and/or is capable of producing) a C4-dicarboxylic acid at a yield of at least than 10%, e.g., at least than 20%, at least than 30%, at least than 40%, at least than 50%, at least than 60%, at least than 70%, at least than 80%, or at least than 90%, of theoretical.
  • the recombinant host has an C4-dicarboxylic acid volumetric productivity (e.g., malic acid volumetric productivity) greater than about 0.1 g/L per hour, e.g., greater than about 0.2 g/L per hour, 0.5 g/L per hour, 0.6 g/L per hour, 0.7 g/L per hour, 0.8 g/L per hour, 0.9 g/L per hour, 1.0 g/L per hour, 1.1 g/L per hour, 1.2 g/L per hour, 1.3 g/L per hour, 1.5 g/L per hour, 1.75 g/L per hour, 2.0 g/L per hour, 2.25 g/L per hour, 2.5 g/L per hour, or 3.0 g/L per hour; or between about 0.1 g/L per hour and about 2.0 g/L per hour, e.g., between about 0.3 g/L per hour and about 1.7 g/L per hour, about 0.5 g/L per hour
  • the recombinant host cells may be cultivated in a nutrient medium suitable for production of the C4-dicarboxylic acid transporter, malate dehydrogenase, or pyruvate carboxylase using methods well known in the art, as described below.
  • the C4-dicarboxylic acid transporter, malate dehydrogenase, and pyruvate carboxylase, and activities thereof, can be detected using methods known in the art. These detection methods may include use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme substrate. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Third Ed., Cold Spring Harbor Laboratory, New York (2001 ); Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, MD (1999 ); and Hanai et al., Appl. Environ. Microbiol. 73:7814-7818 (2007 )).
  • the present disclosure also relates to methods of producing a polypeptide described herein (e.g., a polypeptide comprising or consisting of SEQ ID NO: 2, 4, 6, or any described aspect thereof), comprising: (a) cultivating a cell, which in its wild-type form produces the polypeptide, under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide.
  • the cell is of the genus Aspergillus.
  • the cell is Aspergillus aculeatus.
  • the cell is E. coli NRRL B-50400, E . coli NRRL B-50388, or E. coli NRRL B-50401.
  • the present invention also relates to methods of producing a polypeptide of the present invention, comprising: (a) cultivating a recombinant host cell of the present invention under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide.
  • the host cells are cultivated in a nutrient medium suitable for production of the C4-dicarboxylic acid transporter using methods well known in the art.
  • the cell may be cultivated by shake flask cultivation, and small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated.
  • the cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (e.g., in catalogues of the American Type Culture Collection). If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it can be recovered from cell lysates.
  • the C4-dicarboxylic acid transporter may be detected using methods known in the art that are specific for the polypeptides, as described supra. These detection methods may include use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme substrate. For example, an enzyme assay may be used to determine the activity of the polypeptide.
  • the polypeptide may be recovered using methods known in the art.
  • the polypeptide may be recovered from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.
  • the polypeptide may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing), differential solubility (e.g., ammonium sulfate precipitation), SDS-PAGE, or extraction (see, e.g., Protein Purification, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989 ) to obtain substantially pure polypeptides.
  • chromatography e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion
  • electrophoretic procedures e.g., preparative isoelectric focusing
  • differential solubility e.g., ammonium sulfate precipitation
  • SDS-PAGE or extraction (see, e.g., Protein Purification, J.-C. Janson and Lars Ryden
  • polypeptide is not recovered, but rather a host cell of the present invention expressing a polypeptide is used as a source of the polypeptide.
  • the present invention also relates to plants, e.g., a transgenic plant, plant part, or plant cell, comprising an isolated polynucleotide of the present invention so as to express and produce the polypeptide in recoverable quantities.
  • the polypeptide may be recovered from the plant or plant part.
  • the plant or plant part containing the polypeptide may be used as such for improving the quality of a food or feed, e.g., improving nutritional value, palatability, and rheological properties, or to destroy an antinutritive factor.
  • the transgenic plant can be dicotyledonous (a dicot) or monocotyledonous (a monocot).
  • monocot plants are grasses, such as meadow grass (blue grass, Poa), forage grass such as Festuca, Lolium, temperate grass, such as Agrostis, and cereals, e.g., wheat, oats, rye, barley, rice, sorghum, and maize (corn).
  • dicot plants are tobacco, legumes, such as lupins, potato, sugar beet, pea, bean and soybean, and cruciferous plants (family Brassicaceae), such as cauliflower, rape seed, and the closely related model organism Arabidopsis thaliana .
  • plant parts are stem, callus, leaves, root, fruits, seeds, and tubers as well as the individual tissues comprising these parts, e.g., epidermis, mesophyll, parenchyme, vascular tissues, meristems.
  • Specific plant cell compartments such as chloroplasts, apoplasts, mitochondria, vacuoles, peroxisomes and cytoplasm are also considered to be a plant part.
  • any plant cell, whatever the tissue origin, is considered to be a plant part.
  • plant parts such as specific tissues and cells isolated to facilitate the utilization of the invention are also considered plant parts, e.g., embryos, endosperms, aleurone and seeds coats.
  • the transgenic plant or plant cell expressing a polypeptide may be constructed in accordance with methods known in the art.
  • the plant or plant cell is constructed by incorporating one or more (e.g., two, several) expression constructs encoding a polypeptide into the plant host genome or chloroplast genome and propagating the resulting modified plant or plant cell into a transgenic plant or plant cell.
  • the expression construct is conveniently a nucleic acid construct that comprises a polynucleotide encoding a polypeptide operably linked with appropriate regulatory sequences required for expression of the polynucleotide in the plant or plant part of choice.
  • the expression construct may comprise a selectable marker useful for identifying host cells into which the expression construct has been integrated and DNA sequences necessary for introduction of the construct into the plant in question (the latter depends on the DNA introduction method to be used).
  • regulatory sequences such as promoter and terminator sequences and optionally signal or transit sequences
  • expression of the gene encoding a polypeptide may be constitutive or inducible, or may be developmental, stage or tissue specific, and the gene product may be targeted to a specific tissue or plant part such as seeds or leaves.
  • Regulatory sequences are, for example, described by Tague et al., 1988, Plant Physiology 86: 506 .
  • the 35S-CaMV, the maize ubiquitin 1, and the rice actin 1 promoter may be used ( Franck et al., 1980, Cell 21: 285-294 ; Christensen et al., 1992, Plant Mol. Biol. 18: 675-689 ; Zhang et al., 1991, Plant Cell 3: 1155-1165 ).
  • Organ-specific promoters may be, for example, a promoter from storage sink tissues such as seeds, potato tubers, and fruits ( Edwards and Coruzzi, 1990, Ann. Rev. Genet. 24: 275-303 ), or from metabolic sink tissues such as meristems ( Ito et al., 1994, Plant Mol. Biol.
  • a seed specific promoter such as the glutelin, prolamin, globulin, or albumin promoter from rice ( Wu et al., 1998, Plant Cell Physiol. 39: 885-889 ), a Vicia faba promoter from the legumin B4 and the unknown seed protein gene from Vicia faba ( Conrad et al., 1998, J. Plant Physiol. 152: 708-711 ), a promoter from a seed oil body protein ( Chen et al., 1998, Plant Cell Physiol.
  • the storage protein napA promoter from Brassica napus , or any other seed specific promoter known in the art, e.g., as described in WO 91/14772 .
  • the promoter may be a leaf specific promoter such as the rbcs promoter from rice or tomato ( Kyozuka et al., 1993, Plant Physiol. 102: 991-1000 ), the chlorella virus adenine methyltransferase gene promoter ( Mitra and Higgins, 1994, Plant Mol. Biol. 26: 85-93 ), the aldP gene promoter from rice ( Kagaya et al., 1995, Mol. Gen. Genet.
  • the promoter may inducible by abiotic treatments such as temperature, drought, or alterations in salinity or induced by exogenously applied substances that activate the promoter, e.g., ethanol, oestrogens, plant hormones such as ethylene, abscisic acid, and gibberellic acid, and heavy metals.
  • a promoter enhancer element may also be used to achieve higher expression of a polypeptide in the plant.
  • the promoter enhancer element may be an intron that is placed between the promoter and the polynucleotide encoding a polypeptide.
  • the promoter enhancer element may be an intron that is placed between the promoter and the polynucleotide encoding a polypeptide.
  • Xu et al., 1993, supra disclose the use of the first intron of the rice actin 1 gene to enhance expression.
  • the selectable marker gene and any other parts of the expression construct may be chosen from those available in the art.
  • the nucleic acid construct is incorporated into the plant genome according to conventional techniques known in the art, including Agrobacterium-mediated transformation, virus-mediated transformation, microinjection, particle bombardment, biolistic transformation, and electroporation ( Gasser et al., 1990, Science 244: 1293 ; Potrykus, 1990, Bio/Technology 8: 535 ; Shimamoto et al., 1989, Nature 338: 274 ).
  • Agrobacterium tumefaciens -mediated gene transfer is the method of choice for generating transgenic dicots (for a review, see Hooykas and Schilperoort, 1992, Plant Mol. Biol. 19: 15-38 ) and can also be used for transforming monocots, although other transformation methods are often used for these plants.
  • the method of choice for generating transgenic monocots is particle bombardment (microscopic gold or tungsten particles coated with the transforming DNA) of embryonic calli or developing embryos ( Christou, 1992, Plant J. 2: 275-281 ; Shimamoto, 1994, Curr. Opin. Biotechnol.
  • the transformants having incorporated the expression construct are selected and regenerated into whole plants according to methods well known in the art.
  • the transformation procedure is designed for the selective elimination of selection genes either during regeneration or in the following generations by using, for example, co-transformation with two separate T-DNA constructs or site specific excision of the selection gene by a specific recombinase.
  • transgenic plants may be made by crossing a plant having the construct to a second plant lacking the construct.
  • a construct encoding a polypeptide can be introduced into a particular plant variety by crossing, without the need for ever directly transforming a plant of that given variety. Therefore, the present invention encompasses not only a plant directly regenerated from cells which have been transformed in accordance with the present invention, but also the progeny of such plants.
  • progeny may refer to the offspring of any generation of a parent plant prepared in accordance with the present invention.
  • Such progeny may include a DNA construct prepared in accordance with the present invention, or a portion of a DNA construct prepared in accordance with the present invention.
  • Crossing results in the introduction of a transgene into a plant line by cross pollinating a starting line with a donor plant line. Non-limiting examples of such steps are further articulated in U.S. Patent No: 7,151,204 .
  • Plants may be generated through a process of backcross conversion.
  • plants include plants referred to as a backcross converted genotype, line, inbred, or hybrid.
  • Genetic markers may be used to assist in the introgression of one or more transgenes of the invention from one genetic background into another. Marker assisted selection offers advantages relative to conventional breeding in that it can be used to avoid errors caused by phenotypic variations. Further, genetic markers may provide data regarding the relative degree of elite germplasm in the individual progeny of a particular cross. For example, when a plant with a desired trait which otherwise has a non-agronomically desirable genetic background is crossed to an elite parent, genetic markers may be used to select progeny which not only possess the trait of interest, but also have a relatively large proportion of the desired germplasm. In this way, the number of generations required to introgress one or more traits into a particular genetic background is minimized.
  • the present invention also relates to methods of producing a polypeptide of the present invention comprising: (a) cultivating a transgenic plant or a plant cell comprising a polynucleotide encoding the polypeptide under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide.
  • the present invention is also directed to methods of using the polypeptides having C4-dicarboxylic acid transporter activity, or polynucleotides encoding the polypeptides having C4-dicarboxylic acid transporter activity.
  • the C4-dicarboxylic acid transporters described herein or polynucleotides encoding the same may be used in a host cell (e.g., a filamentous fungal host cell) to aid in the production, such as increasing production, of a C4-dicarboxylic acid (e.g., malic acid).
  • any of the polynucleotides or polypeptides of the present invention described herein e.g., SEQ ID NO: 1, 2, 3, 4, 5, and/or 6, or any described aspect thereof
  • SEQ ID NO: 1, 2, 3, 4, 5, and/or 6, or any described aspect thereof may be used, as exemplified in the aspects set forth below.
  • the present invention relates to methods of producing a C4-dicarboxylic acid (e.g., malic acid), comprising: (1) cultivating a host cell (e.g., filamentous fungal host cell) comprising a heterologous polynucleotide encoding a C4-dicarboxylic acid transporter described herein (e.g., SEQ ID NO: 3, or any described aspect thereof), wherein the host cell secretes increased levels of the C4-dicarboxylic acid compared to the host cell without the heterologous polynucleotide encoding a C4-dicarboxylic acid transporter; and (2) recovering the malic acid.
  • a host cell e.g., filamentous fungal host cell
  • a heterologous polynucleotide encoding a C4-dicarboxylic acid transporter described herein e.g., SEQ ID NO: 3, or any described aspect thereof
  • the present invention relates to methods for increasing C4-dicarboxylic acid production (e.g., malic acid production) relative to a parent host cell, comprising: (1) transforming into a host cell (e.g., a filamentous fungal host cell) a heterologous polynucleotide encoding a C4-dicarboxylic acid transporter described herein (e.g., SEQ ID NO: 3, or any described aspect thereof), wherein the host cell secretes an increased level of C4-dicarboxylic acid compared to the filamentous fungal host cell without the heterologous polynucleotide; (2) cultivating the transformed organism in a medium; and (3) recovering the C4-dicarboxylic acid.
  • a host cell e.g., a filamentous fungal host cell
  • a heterologous polynucleotide encoding a C4-dicarboxylic acid transporter described herein (e.g., SEQ ID NO: 3, or any described aspect thereof)
  • the C4-dicarboxylic acid is malic acid, succinic acid, oxaloacetic acid, malonic acid, or fumaric acid, or combinations thereof. In some aspects, the C4-dicarboxylic acid is malic acid, succinic acid, or fumaric acid, or combinations thereof. In some aspects, the C4-dicarboxylic acid is malic acid or fumaric acid, or a combination of malic acid and fumaric acid. In some aspects, the C4-dicarboxylic acid is malic acid.
  • the C4-dicarboxylic acid transporter may be any C4-dicarboxylic acid transporters described herein, e.g., a C4-dicarboxylic acid transporter selected from: (a) a polypeptide having at least 80% sequence identity to SEQ ID NO: 4, or the mature polypeptide sequence thereof; (b) a polypeptide encoded by a polynucleotide that hybridizes under low stringency conditions with SEQ ID NO: 3, the mature polypeptide coding sequence thereof, or a full-length complementary strand of the foregoing; (c) a polypeptide encoded by a polynucleotide having at least 80% sequence identity to SEQ ID NO: 3, or the mature polypeptide coding sequence thereof; (d) a fragment of the polypeptide of (a), (b), , or (c).
  • a C4-dicarboxylic acid transporter selected from: (a) a polypeptide having at least 80% sequence identity to SEQ ID NO: 4, or
  • the present invention relates to a method of producing a C4-dicarboxylic acid (e.g., malic acid), comprising:
  • the C4-dicarboxylic acid (e.g., malic acid) is produced or secreted at a titer greater than about 10 g/L, e.g., greater than about 25 g/L, 50 g/L, 75 g/L, 100 g/L, 125 g/L, 150 g/L, 160 g/L, 170 g/L, 180 g/L, 190 g/L, 200 g/L, 210 g/L, 225 g/L, 250 g/L, 275 g/L, 300 g/L, 325 g/L, 350 g/L, 400 g/L, or 500g/L; or between about 10 g/L and about 500 g/L, e.g., between about 50 g/L and about 350 g/L, about 100 g/L and about 300 g/L, about 150 g/L and about 250 g/L, about 175 g
  • the level of the produced or secreted C4-dicarboxylic acid (e.g., malic acid) in the host cell is increased by at least 25%, e.g., at least 50%, at least 100%, at least 150%, at least 200%, at least 300%, or at 500% compared to the host cell without the polynucleotide encoding the heterologous polynucleotide when cultivated under the same conditions.
  • the heterologous polynucleotide may be operably linked to a promoter foreign to the polynucleotide.
  • the host cell may further comprise a heterologous second polynucleotide encoding a malate dehydrogenase (e.g., the mature polypeptide coding sequence of SEQ ID NO: 11, or any described aspect thereof) and/or a heterologous third polynucleotide encoding a pyruvate carboxylase (e.g., the mature polypeptide coding sequence of SEQ ID NO: 15, or any described aspect thereof), as described supra.
  • the heterologous second and/or third polynucleotide is operably linked to a promoter foreign to the polynucleotide.
  • malate dehydrogenases and pyruvate carboxylases that may be used with these methods can be found, for example, in PCT Application No. PCT/US10/47002 , entitled “Methods for Improving Malic Acid Production in Filamentous Fungi” filed August 27, 2010, the content of which is hereby incorporated by reference in its entirety, particularly with respect to the polynucleotides encoding malate dehydrogenase and pyruvate carboxylase polypeptides described therein.
  • the host cell may be any host cell described above, e.g., a filamentous fungal host cell, such as a host cell selected from the group consisting of an Acremonium, Aspergillus, Aureobasidium, Bjerkandera, Ceriporiopsis, Chrysosporium, Coprinus, Coriolus , Cryptococcus , Filibasidium, Fusarium, Humicola , Magnaporthe , Mucor, Myceliophthora , Neocallimastix, Neurospora , Paecilomyces, Penicillium , Phanerochaete, Phlebia, Piromyces, Pleurotus , Rhizopus, Schizophyllum, Talaromyces, Thermoascus, Thielavia, Tolypocladium , Trametes, and Trichoderma.
  • the host cell may be an Aspergillus host cell, such as an Aspergillus
  • the recombinant host cell is cultivated in a nutrient medium suitable for production of the C4-dicarboxylic acid transporter, using methods well known in the art, as described supra.
  • the recombinant C4-dicarboxylic acid can be optionally recovered from the fermentation medium using any procedure known in the art (see, for example, WO 1998/022611 and U.S. 7,601,865 ) including, but not limited to, chromatography (e.g., size exclusion chromatography, adsorption chromatography, ion exchange chromatography), electrophoretic procedures, differential solubility, osmosis, distillation, extraction (e.g., liquid-liquid extraction), pervaporation, extractive filtration, membrane filtration, membrane separation, reverse, or ultrafiltration.
  • the C4-dicarboxylic acid is recovered from other material in the fermentation medium by filtration.
  • the recombinant C4-dicarboxylic acid before and/or after being optionally purified is substantially pure.
  • substantially pure intends a recovered preparation of the C4-dicarboxylic acid that contains no more than 15% impurity, wherein impurity intends compounds other than C4-dicarboxylic acids.
  • a preparation of substantially pure C4-dicarboxylic acid wherein the preparation contains no more than 25% impurity, or no more than 20% impurity, or no more than 10% impurity, or no more than 5% impurity, or no more than 3% impurity, or no more than 1% impurity, or no more than 0.5% impurity.
  • Suitable assays to test for the production of C4-dicarboxylic acids for the methods of production and host cells described herein can be performed using methods known in the art.
  • the final C4-dicarboxylic acid product e.g., malic acid
  • the final C4-dicarboxylic acid product can be analyzed by methods such as HPLC (High Performance Liquid Chromatography), GC-MS (Gas Chromatography Mass Spectroscopy) and LC-MS (Liquid Chromatography-Mass Spectroscopy) or other suitable analytical methods using routine procedures well known in the art.
  • HPLC High Performance Liquid Chromatography
  • GC-MS Gas Chromatography Mass Spectroscopy
  • LC-MS Liquid Chromatography-Mass Spectroscopy
  • Byproducts and residual sugar in the fermentation medium can be quantified by HPLC using, for example, a refractive index detector for glucose and alcohols, and a UV detector for organic acids ( Lin et al., Biotechnol. Bioeng. 90:775 -779 (2005 )), or using other suitable assay and detection methods well known in the art.
  • Chemicals used as buffers and substrates were commercial products of at least reagent grade.
  • Aspergillus aculeatus was used as source of the C4-dicarboxylic acid transport protein genes c4t737, c4t521, and mat737.
  • Aspergillus oryzae NRRL 3488 (or ATCC 56747) was used as a source of a pyruvate carboxylase gene, a malate dehydrogenase gene, and for production of the C4-dicarboxylic acids.
  • YEG medium was composed of 20 g glucose, 5 g yeast extract, and deionized water to 1 liter.
  • COVE plates were composed of 1 M sucrose, 2% COVE salt solution, 10 mM acetamide, 15 mM CsCl, and 25 g/l Agar Noble.
  • COVE salt solution was composed of 26 g KCI, 26 g MgSO 4 ⁇ 7H 2 O, 76 g KH 2 PO 4 , 50 ml of COVE trace elements solution, and deionized water to 1 liter.
  • COVE trace elements solution was composed of 0.04 g Na 2 B 4 O 7 ⁇ 10H 2 O, 0.04 g CuSO 4 ⁇ 5H 2 O, 1.2 g FeSO 4 -7H 2 O, 0.7 g MnSO 4 ⁇ H 2 O, 0.8 g Na 2 MoO 2 ⁇ 2H 2 O, 10 g ZnSO 4 ⁇ 7H 2 O and deionized water to 1 liter.
  • Seed medium was composed of 40 g glucose, 6 g Bacto-peptone, 750 mg KH 2 PO 4 , 750 mg K 2 HPO 4 , 100 mg MgSO 4 ⁇ 7H 2 O, 100 mg CaCl 2 ⁇ H 2 O, 5 mg FeSO 4 -7H 2 O, 5 mg NaCl, and deionized water to 1 liter.
  • Seed medium B was composed of 30 g glucose, 3 g Bacto-peptone, 560 mg KH 2 PO 4 , 560 mg K 2 HPO 4 , 925 mg NaH 2 PO 4 ⁇ H 2 O, 820 mg Na 2 HPO 4 , 75 mg MgSO 4 ⁇ 7H 2 O, 75 mg CaCl 2 ⁇ H 2 O, 0.75 ml of 1000X Micronutrient Solution, and deionized water to 1 liter.
  • Acid production medium C was composed of 100 g glucose, 80 g CaCO 3 , 6 g Bacto Peptone, 150 mg KH 2 PO 4 , 150 mg K 2 HPO 4 , 100 mg MgSO 4 ⁇ 7H 2 O, 100 mg CaCl 2 ⁇ H 2 O, 1 ml 1000X Micronutrient Solution, and deionized water to 1 liter.
  • Fermentor batch medium was composed of 120 g glucose, 120 g CaCO 3 , 9 g Bacto-peptone, 150 mg KH 2 PO 4 , 150 mg K 2 HPO 4 , 100 mg MgSO ⁇ 7H 2 O, 100 mg CaCl 2 -2H 2 O, 5 mg FeSO 4 -7H 2 O, 5 mg NaCl, 5 mL Pluronic L61, and deionized water to 1 liter.
  • 1000X Micronutrient Solution was composed of 5 g NaCl, 5 g FeSO 4 ⁇ 7H 2 O, 1 g citric acid, and deionized water to 1 liter.
  • PDA plates were composed of 39 g/l potato dextrose agar.
  • 2XYT+amp plates were composed of 16 g tryptone, 10 g yeast extract, 5 g NaCl, 100 mg ampicillin, 15 g Bacto agar, and deionized water to 1 liter.
  • Example 1 Cloning of an Aspergillus aculeatus C4-dicarboxylic acid transporter gene and construction of expression vector pSaMF35
  • Genomic DNA from Aspergillus aculeatus was isolated by inoculating 100 ml of YEG medium in a shake flask with 2 x 10 6 spores and incubating the flask at 34°C overnight with shaking at 160 rpm.
  • the mycelia were harvested by filtration using a MIRACLOTH® (Calbiochem, San Diego, CA, USA) lined funnel and approximately 2 g of mycelia were recovered and frozen in liquid nitrogen. The frozen mycelia were disrupted by quickly smashing with a hammer while wrapped inside the MIRACLOTH®.
  • the disrupted mycelia were then transferred to a 50 ml polypropylene conical centrifuge tube containing 10ml of 1X lysis buffer (100 mM EDTA, 10 mM Tris pH 8.0, 1% Triton® X-100, 0.5 M Guanidine-HCl, 200 mM NaCl) and 3 ⁇ l of RNase A (QIAGEN Inc., Valencia, CA, USA, 100 mg/ml).
  • the tube was mixed by gentle vortexing, then incubated at room temperature for 5 minutes after which was added 150 ⁇ l Proteinase K (QIAGEN Inc., Valencia, CA, USA; 20 mg/ml).
  • the tube was mixed by inversion and incubated at 50°C for 1 hour.
  • the tube was then centrifuged at 7240 x g for 20 minutes. The supernatant was then added to a pre-equilibrated QIAGEN-tip 100 (QIAGEN Inc., Valencia, CA, USA) and the remaining DNA extraction steps were performed according to the manufacturer's instructions. The DNA was resuspended in 100 ⁇ l TE buffer (10 mM Tris Base, 1 mM EDTA, pH 8.0).
  • the 1194 bp C4-dicarboxylic acid transporter gene c4t737 was amplified from Aspergillus aculeatus genomic DNA using primers 069698 and 069699 shown below.
  • the PCR reaction was composed of 5 ⁇ l 10X reaction buffer (Stratagene, La Jolla, CA, USA), 1 ⁇ l A. aculeatus genomic DNA template (105 ng/ ⁇ l), 1 ⁇ l primer 069698 (100 ng/ ⁇ l), 1 ⁇ l primer 069699 (100 ng/ ⁇ l), 1 ⁇ l dNTP mixture (10 mM), 40.5 ⁇ l deionized water, and 0.5 ⁇ l Herculase® HotStart DNA polymerase (Stratagene, La Jolla, CA, USA). The amplification reaction was incubated in an EPPENDORF® MASTERCYCLER® (Eppendorf Scientific Inc.
  • PCR product was then purified using a MinElute® PCR Purification Kit (QIAGEN Inc., Valencia, CA, USA).
  • Plasmid pShTh60 ( Figure 1 ; see also PCT Application No. PCT/US10/47002, filed August 27, 2010 ) was digested with Sex Al and Pac I, separated by 0.8% agarose gel electrophoresis in TBE buffer (10.8 g/L Tris Base, 5.5 g/L Boric acid, 2 mM EDTA, pH 8.0) and purified using a QIAQUICK® Gel Extraction Kit (QIAGEN Inc., Valencia, CA, USA).
  • the purified PCR product above was then inserted into the digested pShTh60 fragment using an In-FusionTM Advantage reaction kit (Clontech, Mountain View, CA, USA) composed of 2 ⁇ l 5X buffer (Clontech, Mountain View, CA, USA), 2.4 ⁇ l purified PCR product (33 ng/ ⁇ l), 1.5 ⁇ l digested and gel-purified pShTh60 (132 ng/ ⁇ l), 1 ⁇ l In-FusionTM enzyme and 3.1 ⁇ l deionized water.
  • In-FusionTM Advantage reaction kit (Clontech, Mountain View, CA, USA) composed of 2 ⁇ l 5X buffer (Clontech, Mountain View, CA, USA), 2.4 ⁇ l purified PCR product (33 ng/ ⁇ l), 1.5 ⁇ l digested and gel-purified pShTh60 (132 ng/ ⁇ l), 1 ⁇ l In-FusionTM enzyme and 3.1 ⁇ l deionized water.
  • reaction was incubated at 37°C for 15 minutes, 50°C for 15 minutes, placed on ice for 5 minutes and diluted with 40 ⁇ l TE buffer (10 mM Tris Base, 1 mM EDTA, pH 8.0) resulting in pSaMF35 ( Figure 2 ).
  • the nucleotide sequence (SEQ ID NO: 1) and deduced amino acid sequence (SEQ ID NO: 2) of the Aspergillus aculeatus c4t737 gene are shown in Figure 3 .
  • the coding sequence is 1194 bp including the stop codon.
  • the encoded predicted protein is 397 amino acids, with a predicted molecular mass of 44.3 kDa and an isoelectric pH of 6.93.
  • the gene contains no introns.
  • the SignalP program Nielsen et al., 1997, Protein Engineering 10: 1-6
  • a signal peptide of 61 residues was predicted. Based on this program, the predicted mature protein contains 336 amino acids with a predicted molecular mass of 37.3 kDa and an isoelectric pH of 6.52.
  • the predicted mature protein contains 329 amino acids with a predicted molecular mass of 36.5 kDa and an isoelectric pH of 6.52.
  • Protoplast preparation and transformation of Aspergillus oryzae NRRL 3488 were performed by inoculating approximately 2 x 10 7 spores into 100 ml YEG medium and incubating the flask at 27°C for 16-18 hours at 140 rpm.
  • Mycelia were collected by pouring the culture through a sterile funnel lined with MIRACLOTH® (Calbiochem, San Diego, CA, USA) and rinsing with 50 ml of 0.7 M KCI.
  • the washed mycelia were resuspended in a 125 ml flask containing 20 ml of protoplasting solution composed of 5 mg GLUCANEXTM (Novozymes A/S, Bagsv ⁇ rd, Denmark) and 0.5 mg chitinase (Sigma Chemical Co., St. Louis, MO, USA) per ml of 0.7 M KCI (filter sterilized) and incubated at 34°C for 30 minutes with mixing at 80 rpm.
  • the protoplasting solution was poured through a sterile funnel lined with MIRACLOTH® and rinsed with 50 ml of STC buffer (1 M sorbitol-10 mM Tris-HCl pH 6.5-10 mM CaCl 2 ).
  • the flow-through was collected in two 50 ml polypropylene tubes.
  • the tubes were centrifuged at 1300 x g for 10 minutes at room temperature. The supernatant was discarded and the protoplast pellet was resuspended in 20 ml of STC buffer.
  • the protoplasts were washed by two rounds of resuspending the pellet in 20 ml of STC buffer and centrifugation at 1300 x g for 10 minutes at room temperature. The final pellet was resuspended in 2 ml of STC buffer.
  • the protoplasts were counted by removing a 10 ⁇ l sample and counting them in a hemacytometer (VWR, West Chester, PA, USA). The volume was adjusted with STC buffer to obtain a protoplast concentration of 2 x 10 7 per ml.
  • Plasmid pSaMF35 was prepared for transformation by restriction digestion with Pme I.
  • the 4977 bp expression cassette was separated from the digested vector by 0.8% agarose gel electrophoresis in TBE buffer and purified using a QIAQUICK® Gel Extraction Kit.
  • Two transformation reactions were prepared. For each reaction, a 100 ⁇ l solution of protoplast preparation was transferred to a 12 ml polypropylene tube, to which was added 5 ⁇ g of linearized pSaMF35, 250 ⁇ l PEG solution (60% w/v polyethylene glycol (PEG), 10 mM Tris 6.5, 10 mM CaCl) followed by gentle mixing and incubation at 37°C for 30 minutes.
  • PEG polyethylene glycol
  • Example 3 Production of malic acid in shake flask cultures of Aspergillus oryzae transformants containing an expression vector fragment of pSaMF35 (SaMF35)
  • RP-HPLC Reverse Phase High Pressure Liquid Chromatography
  • DAD Diode Array Detector
  • Reverse phase separation was performed using an Aqua 5 ⁇ C18 125 ⁇ 205 x 4.6 mm ID column and AQ C18 4 x 3.0 mm Security Guard Cartridge (Phenomenex, Inc., Torrance, CA, USA).
  • the mobile phase consisted of 10% methanol (HPLC grade) and 90% 145 mM phosphate pH 1.5 buffer.
  • RP-HPLC was performed using an injection volume of 10 ⁇ l at a flow rate of 0.7 ml/minute (isocratic) with a column temperature of 25°C and run time of 11 minutes. Detection was set at 210 nm, 8 nm bandwidth, with the reference at 360 nm, 40 nm bandwidth. The void time was determined to be 3.8 minutes.
  • the quantitative capabilities of the reverse phase method were determined for malic acid by performing replicate injections of serially diluted malic acid standards with concentrations ranging from 49.2-3.93 mM. The relative standard deviation for (RSD) for replicate injections was ⁇ 5%. Malic acid shows R 2 ⁇ 0.9999.
  • Aspergillus oryzae transformant containing pSaMF35 showed an improvement in malic acid production of greater than 2-fold over the Aspergillus oryzae NRRL 3488 control strains after 3 days of shake flask growth.
  • Example 3B Fermentation of Aspergillus oryzae transformants containing an expression vector fragment of pSaMF35 (SaMF35)
  • Example 4 Cloning of an Aspergillus aculeatus C4-dicarboxylic acid transporter gene and construction of expression vector pSaMF36
  • the 1257 bp C4-dicarboxylic acid transporter gene c4t521 was amplified from isolated Aspergillus aculeatus genomic DNA (Example 1) using primers 069700 and 069701 shown below.
  • the PCR reaction was composed of 10 ⁇ l 5X reaction buffer, 1 ⁇ l A. aculeatus genomic DNA template (105 ng/ ⁇ l), 1 ⁇ l primer 069700 (100 ng/ ⁇ l), 1 ⁇ l primer 069701 (100 ng/ ⁇ l), 1 ⁇ l dNTP mixture (10 mM), 35.5 ⁇ l deionized water, and 0.5 ⁇ l PhusionTM Hot Start High-Fidelity DNA polymerase (Finnzymes, Inc, Massachusetts, USA).
  • the amplification reaction was incubated in an EPPENDORF® MASTERCYCLER® programmed for 1 cycle at 98°C for 30 seconds; 30 cycles each at 98°C for 10 seconds, 60°C for 30 seconds, 72°C for 1 minute; and one cycle at 72°C for 10 minutes.
  • the PCR product was digested with Dpn I for 1 hour to degrade any plasmid DNA template.
  • Plasmid pShTh60 ( Figure 1 ) was digested with Sex Al and Pac I, separated by 0.8% agarose gel electrophoresis in TBE buffer, and purified using a QIAQUICK® Gel Extraction Kit. The purified PCR product above was then inserted into the digested pShTh60 fragment using an In-FusionTM Advantage reaction kit composed of 2 ⁇ l 5X buffer, 3 ⁇ l purified PCR product (26 ng/ ⁇ l), 1.5 ⁇ l gel-purified Sex Al and Pac I digested and gel-purified pShTh60 (132 ng/ ⁇ l), 1 ⁇ l In-FusionTM enzyme and 2.5 ⁇ l deionized water. The reaction was incubated at 37°C for 15 minutes, 50°C for 15 minutes, placed on ice for 5 minutes and diluted with 40 ⁇ l TE buffer resulting in pSaMF36 ( Figure 4 ).
  • the nucleotide sequence (SEQ ID NO: 3) and deduced amino acid sequence (SEQ ID NO: 4) of the Aspergillus aculeatus c4t521 gene are shown in Figure 5 .
  • the coding sequence is 1257 bp including the stop codon.
  • the encoded predicted protein is 418 amino acids, with a predicted molecular mass of 46.8 kDa and an isoelectric pH of 6.36.
  • the gene contains no introns.
  • Using the SignalP program Nielsen et al., 1997, Protein Engineering 10: 1-6 ), a signal peptide of 17 residues was predicted. Based on this program, the predicted mature protein contains 401 amino acids with a predicted molecular mass of 44.9 kDa and an isoelectric pH of 6.89.
  • Plasmid pSaMF36 was prepared for transformation by restriction digestion with Pme I.
  • the 5040 bp expression cassette was separated from the digested vector by 0.8% agarose gel electrophoresis in TBE buffer and purified using a QIAQUICK® Gel Extraction Kit.
  • Two transformation reactions were prepared. For each transformation reaction, 100 ⁇ l of protoplast preparation was transferred to a 12 ml polypropylene tube, to which was added 5 ⁇ g of linearized pSaMF36 and 250 ⁇ l PEG solution (60% w/v polyethylene glycol (PEG), 10 mM Tris 6.5, 10 mM CaCl) followed by gentle mixing and incubation at 37°C for 30 minutes.
  • PEG polyethylene glycol
  • Example 6 Production of malic acid in shake flask cultures of Aspergillus oryzae transformants containing an expression vector fragment of pSaMF36 (SaMF36)
  • Table 1 shows the relative increase in malic acid titer of transformants Aspergillus oryzae SaMF36-3 and Aspergillus oryzae SaMF36-4 compared to malic acid production of Aspergillus oryzae NRRL 3488 as a control after 3 days of shake flask growth.
  • Aspergillus oryzae SaMF36-3 and Aspergillus oryzae SaMF36-4 produced an increase in malic acid titer of 2.1-fold and 2.3-fold, respectively, compared to Aspergillus oryzae NRRL 3488.
  • Table 1 Strain Relative titer of malic acid %CV NRRL 3488 1 0.7% SaMF36-3 2.1 4.8% SaMF36-4 2.3 0.2%
  • Example 7 Fermentation of Aspergillus oryzae transformants containing an expression vector fragment of pSaMF36 (SaMF36)
  • Aspergillus oryzae pSaMF36 transformants described in Example 5 and control transformant Aspergillus oryzae ShTh1040 were grown for approximately 7 days at 34°C on PDA plates.
  • a 5-6 ml volume of sterile 50 mM sodium phosphate buffer (pH 6.8) containing 0.2% TWEEN® 80 was added to each plate and spores were suspended by scraping with an inoculating loop. Each suspension was transferred by pipette to a 50 ml conical tube.
  • sterile sodium phosphate buffer 50 mM, pH 6.8 was added to a 500 ml unbaffled flask containing 75 ml of seed medium, which was then inoculated with 2 ml of spore suspension. The flasks were then incubated at 34°C and 180 rpm for about 24 hours. The seed flasks were combined to supply the 144 ml inoculum required per tank.
  • Three-liter fermentors containing 1.8 liters of fermentor batch medium were individually inoculated by introducing 144 ml (8%) of the seed culture broth from the combined seed flasks of either an Aspergillus oryzae pSaMF36 transformant or an Aspergillus oryzae ShTh1040 transformant.
  • the glucose concentration in the fermentor batch medium was reduced to 60 g/L and the feed start was delayed by one day.
  • the fermentors were equilibrated at 34°C ⁇ 0.1 °C and stirred at 500 rpm. Inlet air flow was maintained at 1 v/v/m.
  • a 20% glucose stream was administered at a rate of approximately 7.3 g/hr beginning at about 43 hours of fermentation.
  • Sterile CaCO 3 (about 100 g) was added around day 5 or 6 to keep the fermentation pH in the range of 6 to 7. Samples were withdrawn daily and analyzed for malic acid production as described in Example 3. Fermentation was completed after 7 or 8 days.
  • Example 8 Cloning of an Aspergillus oryzae malate dehydrogenase gene and construction of expression vector pSaMF21
  • Plasmid pSaMF21 was constructed to contain the NAD-dependent malate dehydrogenase ( mdh3 ) gene sequence (DOGAN: AO090701000013), a 1430 bp fragment from Aspergillus oryzae as described in PCT Application No. PCT/US10/47002, filed August 27, 2010 .
  • the nucleotide sequence (SEQ ID NO: 11) and deduced amino acid sequence (SEQ ID NO: 12) of the Aspergillus oryzae NRRL 3488 malate dehydrogenase mdh3 gene are shown in Figure 6 .
  • the genomic coding sequence of 1430 bp (including stop codon) encodes a polypeptide of 330 amino acids with a predicted mass of 35 kDa.
  • the coding sequence is interrupted by 7 introns of 57 bp (14-70 bp), 70 bp (103-172 bp), 74 bp (284-357 bp), 68 bp (446-513 bp), 58 bp (892-949 bp), 48 bp (1035-1082 bp), and 62 bp (1228-1289 bp).
  • the G+C content of the coding region of the mdh3 gene is 50.3%.
  • the plasmid was constructed by linearizing pShTh60 ( Figure 1 ) by restriction digestion with Sex Al and Pac I.
  • the digested vector was separated by 0.8% agarose gel electrophoresis in TBE buffer and purified using a QIAQUICK® Gel Extraction Kit.
  • the mdh3 gene was amplified from pShTh71 (PCT Application No. PCT/US10/47002, filed August 27, 2010 ) using primers 067522 and 067525.
  • the PCR reaction was composed of 5 ⁇ l 10X reaction buffer, 1 ⁇ l pShTh71 template (87 ng/ ⁇ l), 1 ⁇ l primer 067522 (100 ng/ ⁇ l), 1 ⁇ l primer 067525 (100 ng/ ⁇ l), 1 ⁇ l dNTP mixture (10 mM), 45.5 ⁇ l deionized water, and 0.5 ⁇ l Herculase® HotStart DNA polymerase (Stratagene, La Jolla, CA, USA).
  • the amplification reaction was incubated in an EPPENDORF® MASTERCYCLER® programmed for 1 cycle at 95°C for 2 minutes; 10 cycles each at 95°C for 10 seconds, 58°C for 30 seconds, and 72°C for 1.5 minutes; 20 cycles each at 95°C for 10 seconds, 50°C for 30 seconds, and 72°C for 1.5 minutes plus 10 seconds per cycle.
  • the PCR reaction was subjected to a restriction digest with Dpn I for 1 hour to degrade any plasmid DNA template.
  • the PCR product was then purified using the MinElute® PCR Purification Kit (QIAGEN Inc., Valencia, CA, USA).
  • the purified PCR product was inserted into the vector using an In-FusionTM Advantage reaction composed of 2 ⁇ l 5X buffer, 0.5 ⁇ l purified PCR product (110 ng/ ⁇ l), 1.7 ⁇ l gel-purified Sex Al and Pac I restriction digested pShTh60 ( Figure 1 ; 78 ng/ ⁇ l), 1 ⁇ l In-FusionTM enzyme and 4.8 ⁇ l deionized water.
  • the reaction was incubated at 37°C for 15 minutes followed by 50°C for 15 minutes after which it was placed on ice for 5 minutes and diluted with 40 ⁇ l TE buffer resulting in pSaMF21 ( Figure 7 ).
  • Example 9 Cloning of an Aspergillus oryzae pyruvate carboxylase gene and construction of expression vector pRyan1
  • Plasmid pRyan1 was constructed to contain the pyruvate carboxylase (pyc) gene sequence (DOGAN: AO090023000801), a 3646 bp fragment from Aspergillus oryzae (including two stop codons) as described in PCT Application No. PCT/US10/47002, filed August 27, 2010 .
  • the nucleotide sequence (SEQ ID NO: 15) and deduced amino acid sequence (SEQ ID NO: 16) of the Aspergillus oryzae pyruvate carboxylase genes are shown in Figures 8A and 8B .
  • Both the Aspergillus oryzae NRRL 3488 and ATCC 56747 pyruvate carboxylase genes have the same nucleotide sequence.
  • the genomic coding sequence of 3643 bp (including one stop codon) encodes a polypeptide of 1193 amino acids with a predicted mass of 131 kDa.
  • the coding sequence is interrupted by 1 intron of 61 bp (3475-3535 bp).
  • the G+C content of the coding region of the gene is 57.1%.
  • the plasmid was constructed by linearizing pShTh60 ( Figure 1 ) by restriction digestion with Sex Al and Pac I.
  • the digested vector was separated by 0.8% agarose gel electrophoresis in TBE buffer and purified using a QIAQUICK® Gel Extraction Kit.
  • the pyc gene was amplified from Aspergillus oryzae NRRL 3488 genomic DNA using primers 066549 and 067388 shown below.
  • the PCR reaction was composed of 5 ⁇ l 10X reaction buffer, 1 ⁇ l Aspergillus oryzae NRRL3488 genomic DNA (110 ng/ ⁇ l), 1 ⁇ l primer 066549 (100 ng/ ⁇ l), 1 ⁇ l primer 067388 (100 ng/ ⁇ l), 1 ⁇ l dNTP mixture (10 mM), 45.5 ⁇ l deionized water, and 0.5 ⁇ l Herculase® HotStart DNA polymerase.
  • the amplification reaction was incubated in an EPPENDORF® MASTERCYCLER® programmed for 1 cycle at 95°C for 2 minutes; 10 cycles each at 95°C for 10 seconds, 58°C for 30 seconds, and 72°C for 3.5 minutes; 20 cycles each at 95°C for 10 seconds, 58°C for 30 seconds, and 72°C for 3.5 minutes plus 10 seconds per cycle.
  • the PCR product was then purified using a MinElute® PCR Purification Kit.
  • the purified PCR product was inserted into the vector using an In-FusionTM Advantage reaction composed of 2 ⁇ l 5X buffer, 1 ⁇ l purified PCR product (144 ng/ ⁇ l), 2 ⁇ l gel purified Sex Al and Pac I restriction digested pShTh60 ( Figure 1 ; 78 ng/ ⁇ l), 1 ⁇ l In-FusionTM enzyme and 4 ⁇ l deionized water.
  • the reaction was incubated at 37°C for 15 minutes followed by 50°C for 15 minutes after which it was placed on ice for 5 minutes and diluted with 40 ⁇ l TE buffer resulting in pRYAN1 ( Figure 9 ).
  • a 2 ⁇ l aliquot of the ligation reaction was transformed into ONE SHOT@ TOP10 chemically competent E.
  • Example 10 Transformation of expression vector fragments of pSaMF36, pSaMF21 and pRyan1 into Aspergillus oryzae NRRL 3488 (SaMF3603)
  • the vectors pSaMF36 (Example 4), pSaMF21 (Example 8) and pRyan1 (Example 9) were prepared for transformation by digestion with Pme I for 4 hours at 37°C.
  • the digested vectors were separated on a 0.8% agarose TBE gel, a 5040 bp band was cut out for pSaMF36, a 5213 bp band was cut out for pSaMF21 and a 7429 bp band was cut out for pRyan1.
  • the bands containing the expression cassettes were each purified using the Macherey-Nagel Nucleospin® Extract II Kit (Duren, Germany) according to manufacturer's instructions.
  • transformation reactions were prepared. For each transformation reaction, 100 ⁇ l of protoplast preparation (Example 2) were transferred to a 12 ml polypropylene tube. To this was added a total of five micrograms of amp marker free, linearized pShTh104, pSaMF21 and pRyan1 in equimolar quantities and 250 ⁇ l of polyethylene glycol (PEG) solution (60% w/v polyethylene glycol (PEG), 10 mM Tris 6.5, 10 mM CaCl) followed by gentle mixing and incubation at 37°C for 30 minutes. Each transformation was diluted with 9 ml of STC buffer, followed by plating three separate 3ml aliquots onto COVE plates.
  • PEG polyethylene glycol
  • Example 11 Production of malic acid in shake flask cultures of Aspergillus oryzae transformants containing expression vector fragments of pSaMF36, pSaMF21 and pRyan1 (SaMF3603)
  • Aspergillus oryzae transformants SaMF3603 containing pSaMF36, pSaMF21 and pRyan1 showed an improvement in malic acid production of greater than 2.55-fold over the Aspergillus oryzae NRRL 3488 control strains.
  • Example 12 Fermentation of Aspergillus oryzae transformants containing expression vector fragments of pSaMF36, pSaMF21 and pRyan1 (SaMF3603)
  • Aspergillus oryzae triple transformant SaMF3603 described in Example 10 and control transformant Aspergillus oryzae SaMF2103 were prepared and fermented as described in Example 7.
  • Example 13 Cloning of an Aspergillus aculeatus C4-dicarboxylic acid transporter gene and construction of expression vector pSaMF38
  • the 1194 bp C4-dicarboxylic acid transporter gene mat737 was synthetically constructed into pAaMAT737 ( Figure 10 ; DNA2.0, Menlo Park, CA, USA).
  • the mat737 gene was amplified from pAaMAT737 using primers 069698 and 069699 (Example 1).
  • the PCR reaction was composed of 10 ⁇ l 5X reaction buffer, 1 ⁇ l pAaMAT737 template (20 ng/ ⁇ l), 1 ⁇ l primer 069698 (100 ng/ ⁇ l), 1 ⁇ l primer 069699 (100 ng/ ⁇ l), 1 ⁇ l dNTP mixture (10 mM), 35.5 ⁇ l deionized water, and 0.5 ⁇ l Phusion® Hot Start High-Fidelity DNA polymerase.
  • the amplification reaction was incubated in an EPPENDORF® MASTERCYCLER® programmed for 1 cycle at 98°C for 30 seconds; 30 cycles each at 98°C for 10 seconds, 65°C for 30 seconds, and 72°C for 1 minute; 1 cycle at 72°C for 10 minutes.
  • the PCR reaction was digested with Dpn I for 1 hour to degrade any plasmid DNA template and the PCR product was purified using the MinElute® PCR Purification Kit.
  • Plasmid pShTh60 ( Figure 1 ) was digested with Sex Al and Pac I, separated by 0.8% agarose gel electrophoresis in TBE buffer (10.8 g/L Tris Base, 5.5 g/L Boric acid, 2 mM EDTA, pH 8.0) and purified using a QIAQUICK® Gel Extraction Kit.
  • the purified PCR product above was then inserted into the digested pShTh60 fragment using an In-FusionTM Advantage reaction kit composed of 2 ⁇ l 5X buffer, 0.5 ⁇ l purified PCR product (187 ng/ ⁇ l), 1.5 ⁇ l digested and gel-purified pShTh60 (132 ng/ ⁇ l), 1 ⁇ l In-FusionTM enzyme and 5 ⁇ l deionized water.
  • the reaction was incubated at 37°C for 15 minutes, 50°C for 15 minutes, placed on ice for 5 minutes and diluted with 40 ⁇ l TE buffer (10 mM Tris Base, 1 mM EDTA, pH 8.0) resulting in pSaMF38 ( Figure 11 ).
  • the nucleotide sequence (SEQ ID NO: 5) and deduced amino acid sequence (SEQ ID NO: 6) of the mat737 gene are shown in Figure 12 .
  • the coding sequence is 1194 bp including the stop codon.
  • the encoded predicted protein is 397 amino acids, with a predicted molecular mass of 44.3 kDa and an isoelectric pH of 7.32.
  • the gene contains no introns.
  • InterProScan program The European Bioinformatics Institute
  • a signal peptide of 68 residues was predicted. Based on this program, the predicted mature protein contains 329 amino acids with a predicted molecular mass of 36.6 kDa and an isoelectric pH of 6.52.
  • Plasmid pSaMF38 was prepared for transformation by restriction digestion with Pme I.
  • the 4977 bp expression cassette was separated from the digested vector by 0.8% agarose gel electrophoresis in TBE buffer and purified using a Macherey-Nagel Nucleospin Extract II Kit.
  • Two transformation reactions were prepared. For each transformation reaction, 100 ⁇ l of protoplast preparation was transferred to a 12 ml polypropylene tube, to which was added 5 ⁇ g of linearized pSaMF38 and 250 ⁇ l PEG solution (60% w/v polyethylene glycol (PEG), 10 mM Tris 6.5, 10 mM CaCl) followed by gentle mixing and incubation at 37°C for 30 minutes.
  • PEG polyethylene glycol
  • Example 15 Production of malic acid in shake flask cultures of Aspergillus oryzae transformants containing an expression vector fragment of pSaMF38 (SaMF38)
  • Aspergillus oryzae pSaMF38 transformant showed an improvement in malic acid production of greater than 1.8-fold over the Aspergillus oryzae NRRL 3488 control strains.
  • Example 16 Cloning of an Aspergillus aculeatus C4-dicarboxylic acid transporter gene and construction of expression vector pSaMF41 under control of an alternative promoter
  • the 1257 bp C4-dicarboxylic acid transporter gene c4t521 was amplified from pSaMF36 ( supra ) using primers 0611384 and 069701 shown below.
  • the PCR reaction was composed of 5 ⁇ l 10X reaction buffer, 1 ⁇ l pSaMF36 template (50 ng/ ⁇ l), 1 ⁇ l primer 0611384 (100 ng/ ⁇ l), 1 ⁇ l primer 069701 (100 ng/ ⁇ l), 1 ⁇ l dNTP mixture (10 mM), 40.5 ⁇ l deionized water, and 0.5 ⁇ l Herculase® HotStart DNA polymerase (Stratagene, La Jolla, CA, USA).
  • the amplification reaction was incubated in an EPPENDORF® MASTERCYCLER® programmed for 1 cycle at 95°C for 2 minutes; 10 cycles each at 95°C for 10 seconds, 60°C for 30 seconds, and 72°C for 1.5 minutes; 20 cycles each at 95°C for 10 seconds, 60°C for 30 seconds, and 72°C for 1.5 minutes plus 10 seconds per cycle.
  • the PCR reaction was subjected to restriction digestion with Dpn I for 1 hour to degrade any plasmid DNA template.
  • the PCR product was then purified using the MinElute® PCR Purification Kit (QIAGEN Inc.).
  • the purified PCR product was then inserted into a vector containing the gpd promoter (pShTh108) using an In-FusionTM Advantage reaction composed of 2 ⁇ l 5X buffer, 0.6 ⁇ l purified PCR product (127 ng/ ⁇ l), 1.75 ⁇ l gel-purified Hind III and Pac I restriction digested pShTh108 (114 ng/ ⁇ l), 1 ⁇ l In-FusionTM enzyme and 4.65 ⁇ l deionized water. The reaction was incubated at 37°C for 15 minutes then 50°C for 15 minutes, and then placed on ice for 5 minutes and diluted with 40 ⁇ l TE buffer resulting in pSaMF41.
  • In-FusionTM Advantage reaction composed of 2 ⁇ l 5X buffer, 0.6 ⁇ l purified PCR product (127 ng/ ⁇ l), 1.75 ⁇ l gel-purified Hind III and Pac I restriction digested pShTh108 (114 ng/ ⁇ l), 1 ⁇ l In-FusionTM enzyme and 4.65
  • the nucleotide sequence (SEQ ID NO: 3) and deduced amino acid sequence (SEQ ID NO: 4) of the Aspergillus aculeatus c4t521 gene are shown in Figure 5 .
  • the coding sequence is 1257 bp including the stop codon and is driven by the gpd promoter compared to the pgk promoter of Example 4.
  • Plasmid pSaMF41 was prepared for transformation by linearizing by restriction digestion with Pme I.
  • the 5025 bp expression cassette was separated from the digested vector by 0.8% agarose gel electrophoresis in TBE buffer and purified using a Macherey-Nagel Nucleospin® Extract II Kit for gel isolation according to manufacturer's instructions.
  • Two transformation reactions were prepared. For each transformation reaction, 100 ⁇ l of protoplast preparation was transferred to a 12 ml polypropylene tube.
  • Example 18 Production of malic acid in shake flask cultures of Aspergillus oryzae transformants containing an expression vector fragment of pSaMF41 (SaMF41)
  • Aspergillus oryzae SaMF41 transformants containing Aspergillus aculeatus c4t521 gene (SEQ ID NO: 3) driven by the gpd promoter showed comparable malic acid production to Aspergillus oryzae SaMF36 transformants containing Aspergillus aculeatus c4t521 gene (SEQ ID NO: 3) driven by the pgk promoter, and an increase in malic acid titer of about 2-fold compared to Aspergillus oryzae NRRL 3488 control lacking the c4t521 gene.
  • Example 19 Fermentation of Aspergillus oryzae transformants containing an expression vector fragment of pSaMF41 (SaMF41)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Claims (19)

  1. Polypeptide isolé ayant une activité de transporteur d'acide dicarboxylique C4, sélectionné parmi :
    (a) un polypeptide présentant au moins 80 %, au moins 85 %, au moins 90 %, au moins 91 %, au moins 92 %, au moins 93 %, au moins 94 %, au moins 95 %, au moins 96 %, au moins 97 %, au moins 98 %, au moins 99 %, ou 100 % d'identité de séquence avec SEQ ID No: 4, ou la séquence du polypeptide mature de celle-ci, dans lequel la séquence du polypeptide mature de SEQ ID No: 4 correspond aux acides aminés 18 à 418 de SEQ ID No: 4;
    (b) un polypeptide codé par un polynucléotide qui s'hybride dans des conditions de stringence élevée, ou des conditions de stringence très élevée avec SEQ ID No: 3, la séquence codant pour le polypeptide mature de celle-ci, dans lequel la séquence codant pour le polypeptide mature de SEQ ID No: 3 correspond aux nucléotides 52 à 1257 de SEQ ID No: 3, ou le brin complémentaire pleine longueur de celle-ci ;
    (c) un polypeptide codé par un polynucléotide présentant au moins 80 %, au moins 85 %, au moins 90 %, au moins 91 %, au moins 92 %, au moins 93 %, au moins 94 %, au moins 95 %, au moins 96 %, au moins 97 %, au moins 98 %, au moins 99 %, ou 100 % d'identité de séquence avec SEQ ID No: 3, la séquence codant pour le polypeptide mature de celle-ci, dans lequel la séquence codant pour le polypeptide mature de SEQ ID No: 3 correspond aux nucléotides 52 à 1257 de SEQ ID No: 3 ;
    (d) un fragment d'un polypeptide de (a), (b) ou (c) qui a une activité de transporteur d'acide dicarboxylique C4.
  2. Polypeptide selon la revendication 1, comprenant ou consistant en SEQ ID No: 4.
  3. Polypeptide selon l'une quelconque des revendications 1-2, comprenant ou consistant en le polypeptide mature de SEQ ID No: 4.
  4. Polypeptide selon la revendication 3, dans lequel le polypeptide mature de SEQ ID No: 4 correspond aux acides aminés 18 à 418 de SEQ ID No: 4.
  5. Polypeptide selon l'une quelconque des revendications 1 à 4, dans lequel le polypeptide est codé par le polynucléotide contenu dans le plasmide pAaC4t521 contenu dans E. coli NRRL B-50388.
  6. Composition comprenant le polypeptide selon l'une quelconque des revendications 1 à 5.
  7. Polynucléotide isolé codant pour le polypeptide selon l'une quelconque des revendications 1 à 5.
  8. Construction d'acide nucléique ou vecteur d'expression comprenant le polynucléotide selon la revendication 7 lié de manière opérationnelle à une ou plusieurs séquences de contrôle qui dirige(nt) la production du polypeptide chez un hôte d'expression.
  9. Cellule hôte recombinante comprenant le polynucléotide selon la revendication 7 lié de manière opérationnelle à une ou plusieurs séquences de contrôle qui dirige(nt) la production du polypeptide.
  10. Cellule hôte comprenant un polynucléotide hétérologue qui code pour un transporteur d'acide dicarboxylique C4, dans laquelle le polynucléotide hétérologue :
    (a) code pour un transporteur d'acide dicarboxylique C4 présentant au moins 80 %, au moins 85 %, au moins 90 %, au moins 91 %, au moins 92 %, au moins 93 %, au moins 94 %, au moins 95 %, au moins 96 %, au moins 97 %, au moins 98 %, au moins 99 %, ou 100 % d'identité de séquence avec SEQ ID No: 4, ou la séquence du polypeptide mature de celle-ci, dans laquelle la séquence du polypeptide mature de SEQ ID No: 4 correspond aux acides aminés 18 à 418 de SEQ ID No: 4 ; ou
    (b) présente au moins 80 %, au moins 85 %, au moins 90 %, au moins 91 %, au moins 92 %, au moins 93 %, au moins 94 %, au moins 95 %, au moins 96 %, au moins 97 %, au moins 98 %, au moins 99 %, ou 100 % d'identité de séquence avec SEQ ID No: 3, la séquence codant pour le polypeptide mature de celle-ci, dans laquelle la séquence codant pour le polypeptide mature de SEQ ID No: 3 correspond aux nucléotides 53 à 1257 de SEQ ID No: 3 ;
    dans laquelle la cellule hôte est capable de produire une plus grande quantité d'acide dicarboxylique C4 comparativement à la même cellule hôte sans le polynucléotide hétérologue quand elles sont cultivées dans les mêmes conditions.
  11. Cellule hôte selon la revendication 10, dans laquelle le polynucléotide hétérologue est lié de manière opérationnelle à un promoteur étranger au polynucléotide.
  12. Cellule hôte selon la revendication 10 ou 11, comprenant en outre un second polynucléotide hétérologue codant pour une malate déshydrogénase.
  13. Cellule hôte selon l'une quelconque des revendications 10 à 12, comprenant en outre un troisième polynucléotide hétérologue codant pour une pyruvate carboxylase.
  14. Cellule hôte selon l'une quelconque des revendications 10 à 13, dans laquelle la cellule hôte est une cellule hôte de type champignon filamenteux.
  15. Cellule hôte de type champignon filamenteux selon la revendication 14, dans laquelle la cellule hôte est une cellule hôte Aspergillus.
  16. Cellule hôte de type champignon filamenteux selon la revendication 15, dans laquelle la cellule hôte est une cellule hôte Aspergillus oryzae.
  17. Cellule hôte selon l'une quelconque des revendications 10 à 16, dans laquelle l'acide dicarboxylique C4 est l'acide malique.
  18. Méthode de production d'un acide dicarboxylique C4, comprenant :
    (a) la culture de la cellule hôte selon l'une quelconque des revendications 10 à 17 dans un milieu dans des conditions aptes à produire un acide dicarboxylique C4 ; et
    (b) la récupération de l'acide dicarboxylique C4.
  19. Méthode pour accroître la production d'acide dicarboxylique C4, comprenant :
    (a) la transformation dans une cellule hôte d'un polynucléotide hétérologue codant pour le polypeptide selon l'une quelconque des revendications 1 à 5 ;
    (b) la culture de la cellule hôte transformée dans un milieu dans des conditions aptes à produire un acide dicarboxylique C4 ; et
    (c) la récupération de l'acide dicarboxylique C4.
EP14162246.4A 2010-06-21 2011-06-21 Polypeptides possédant une activité de transporteur d'acide dicarboxylique en C4 et polynucléotides codant pour ces derniers Not-in-force EP2769985B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35686810P 2010-06-21 2010-06-21
EP11728506.4A EP2582716A1 (fr) 2010-06-21 2011-06-21 Polypeptides possédant une activité de transporteur d'acide dicarboxylique en c4 et polynucléotides codant pour ces derniers

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP11728506.4A Division EP2582716A1 (fr) 2010-06-21 2011-06-21 Polypeptides possédant une activité de transporteur d'acide dicarboxylique en c4 et polynucléotides codant pour ces derniers

Publications (2)

Publication Number Publication Date
EP2769985A1 EP2769985A1 (fr) 2014-08-27
EP2769985B1 true EP2769985B1 (fr) 2017-12-06

Family

ID=44314352

Family Applications (2)

Application Number Title Priority Date Filing Date
EP14162246.4A Not-in-force EP2769985B1 (fr) 2010-06-21 2011-06-21 Polypeptides possédant une activité de transporteur d'acide dicarboxylique en C4 et polynucléotides codant pour ces derniers
EP11728506.4A Withdrawn EP2582716A1 (fr) 2010-06-21 2011-06-21 Polypeptides possédant une activité de transporteur d'acide dicarboxylique en c4 et polynucléotides codant pour ces derniers

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP11728506.4A Withdrawn EP2582716A1 (fr) 2010-06-21 2011-06-21 Polypeptides possédant une activité de transporteur d'acide dicarboxylique en c4 et polynucléotides codant pour ces derniers

Country Status (12)

Country Link
US (3) US8158395B2 (fr)
EP (2) EP2769985B1 (fr)
JP (1) JP5912111B2 (fr)
KR (1) KR20130113937A (fr)
CN (1) CN103080126B (fr)
AU (1) AU2011271094B2 (fr)
BR (1) BR112012029891A2 (fr)
CA (1) CA2803343C (fr)
DK (1) DK2769985T3 (fr)
MX (1) MX2012014627A (fr)
WO (1) WO2011163269A1 (fr)
ZA (1) ZA201209441B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010289725A1 (en) * 2009-09-01 2012-04-05 Novozymes, Inc. Methods for improving malic acid production in filamentous fungi
CN106148208B (zh) * 2015-03-23 2020-12-18 中国科学院天津工业生物技术研究所 新的二元有机酸生产菌株及其制备和应用
CN106148209B (zh) * 2015-03-23 2020-11-20 中国科学院天津工业生物技术研究所 新的二元有机酸生产菌株及其制备和应用
CN109415720B (zh) * 2016-06-29 2021-11-26 花王株式会社 C4二羧酸的制造方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1047002A (en) 1911-04-03 1912-12-10 James S Diehl Scissors.
US3063910A (en) 1960-02-03 1962-11-13 Kyowa Hakko Kogyo Kk Method of producing l-malic acid by fermentation
US5536661A (en) 1987-03-10 1996-07-16 Novo Nordisk A/S Process for the production of protein products in aspergillus
DK122686D0 (da) 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
PT97110B (pt) 1990-03-23 1998-11-30 Gist Brocades Nv Processo para catalisar reaccoes acelaraveis por enzimas, mediante adicao ao meio reaccional de sementes de plantas transgenicas e para obtencao das referidas sementes
US6395966B1 (en) 1990-08-09 2002-05-28 Dekalb Genetics Corp. Fertile transgenic maize plants containing a gene encoding the pat protein
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
DK0765394T3 (da) 1994-06-03 2001-12-10 Novozymes As Oprensede Myceliopthora-laccaser og nukleinsyrer der koder for disse
AU2705895A (en) 1994-06-30 1996-01-25 Novo Nordisk Biotech, Inc. Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein
US5766439A (en) 1996-10-10 1998-06-16 A. E. Staley Manufacturing Co. Production and recovery of organic acids
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US7504490B1 (en) 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
AU6188599A (en) 1998-10-26 2000-05-15 Novozymes A/S Constructing and screening a dna library of interest in filamentous fungal cells
US6511824B1 (en) 1999-03-17 2003-01-28 Exelixis, Inc. Nucleic acids and polypeptides of invertebrate TWIK channels and methods of use
CN100532561C (zh) 1999-03-22 2009-08-26 诺沃奇梅兹有限公司 新的葡糖淀粉酶及编码它的核酸序列
US6531644B1 (en) 2000-01-14 2003-03-11 Exelixis, Inc. Methods for identifying anti-cancer drug targets
AU2002211665B2 (en) 2000-10-12 2005-10-20 Exelixis, Inc. Human Ect2 and methods of use
US7151204B2 (en) 2001-01-09 2006-12-19 Monsanto Technology Llc Maize chloroplast aldolase promoter compositions and methods for use thereof
WO2005073161A1 (fr) 2004-01-29 2005-08-11 Zeachem Inc. Recuperation d'acides organiques
US20080090273A1 (en) 2005-11-21 2008-04-17 Aaron Adriaan Winkler Malic Acid Production in Recombinant Yeast
EP2155885A4 (fr) * 2007-05-18 2010-12-01 Microbia Prec Engineering Inc Production d'acide malique dans une levure recombinée
US20110039327A1 (en) 2007-05-18 2011-02-17 Aaron Adriaan Winkler Organic acid production by fungal cells
ES2383473T3 (es) 2007-11-20 2012-06-21 Dsm Ip Assets B.V. Producción de ácido dicarboxílico en eucariotas
BRPI0913901A2 (pt) 2008-06-17 2016-12-13 Genomatica Inc micro-organismos e métodos para a biossíntese de fumarato, malato e acrilato
EP3176265A1 (fr) 2008-07-08 2017-06-07 DSM IP Assets B.V. Production d'acide dicarboxylique à ph faible
WO2010111344A2 (fr) 2009-03-24 2010-09-30 Microbia, Inc. Procédés et microorganismes pour la production d'acides dicarboxyliques en c4
JP2012223091A (ja) 2009-08-25 2012-11-15 Ajinomoto Co Inc Ｌ−アミノ酸の製造法
AU2010289725A1 (en) 2009-09-01 2012-04-05 Novozymes, Inc. Methods for improving malic acid production in filamentous fungi
CN102947442B (zh) 2009-11-06 2016-03-09 诺维信股份有限公司 用于糖化纤维素材料的组合物
WO2011066304A2 (fr) 2009-11-25 2011-06-03 Codexis, Inc. Polypeptides génétiquement modifiés de l'anhydrase carbonique de classe bêta et utilisations de ceux-ci

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
EP2582716A1 (fr) 2013-04-24
US20130302865A1 (en) 2013-11-14
AU2011271094A1 (en) 2012-11-29
CA2803343A1 (fr) 2011-12-29
CN103080126B (zh) 2016-05-11
ZA201209441B (en) 2013-08-28
MX2012014627A (es) 2013-02-21
WO2011163269A1 (fr) 2011-12-29
KR20130113937A (ko) 2013-10-16
BR112012029891A2 (pt) 2021-07-06
JP5912111B2 (ja) 2016-04-27
CN103080126A (zh) 2013-05-01
US20110312047A1 (en) 2011-12-22
AU2011271094B2 (en) 2015-01-22
US20120149079A1 (en) 2012-06-14
JP2013534825A (ja) 2013-09-09
US8158395B2 (en) 2012-04-17
EP2769985A1 (fr) 2014-08-27
US8518676B2 (en) 2013-08-27
US9303275B2 (en) 2016-04-05
DK2769985T3 (da) 2018-01-29
CA2803343C (fr) 2018-08-07

Similar Documents

Publication Publication Date Title
US8663956B2 (en) Recombinant microorganisms for production C4-dicarboxylic acids
US8497103B2 (en) Methods for C4-dicarboxylic acid production in filamentous fungi
CA2721108A1 (fr) Polypeptides a activite acide ferulique esterase et polynucleotides codant pour ceux-ci
US9447440B2 (en) Microorganisms for C4-dicarboxylic acid production
US11788078B2 (en) Processes for producing ethanol
US9404091B2 (en) Dehydrogenase variants and polynucleotides encoding same
US20110269206A1 (en) Polypeptides Having Catalase Activity And Polynucleotides Encoding Same
US9303275B2 (en) Polypeptides having C4 dicarboxylic acid transporter activity and polynucleotides encoding same
EP2576606B1 (fr) Production d'acides dicarboxyliques en c4 dans des champignons filamenteux
AU2015202004A1 (en) Aspergillus aculeatus derived polypeptides having C4-dicarboxylic acid transporter activity and polynucleotides encoding same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140328

AC Divisional application: reference to earlier application

Ref document number: 2582716

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

17Q First examination report despatched

Effective date: 20160413

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20161010

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20170309

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 2582716

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 952279

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171215

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011044069

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20180126

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180306

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 952279

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180306

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011044069

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20180907

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180630

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180621

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180630

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20190627

Year of fee payment: 9

Ref country code: FI

Payment date: 20190627

Year of fee payment: 9

Ref country code: NL

Payment date: 20190626

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20190627

Year of fee payment: 9

Ref country code: FR

Payment date: 20190625

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20190627

Year of fee payment: 9

Ref country code: GB

Payment date: 20190627

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20110621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171206

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180406

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602011044069

Country of ref document: DE

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20200630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200621

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20200701

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20200621

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200621

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200701

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630